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Abstract 
Invariant natural killer T (iNKT) cells are composed of at least three 
functionally distinct subsets, NKT1, NKT2 and NKT17. Through selective 
activation of these three iNKT effector subsets, iNKT cells can modulate 
immune responses and tissue homeostasis in different fashions. However, the 
developmental steps that drive iNKT cells into functional distinct subsets have 
not been elucidated, and thus their potential to be utilized in anti-cancer or 
autoimmune immunotherapies has not been realized, despite the fact that 
iNKT stimulatory lipids are well-tolerated in human trials. My dissertation 
research aims to fill this knowledge gap by investigating the following aspects 
of iNKT biology: 1) characterizing the multipotent progenitor for the iNKT 
effector subsets (in chapter 2); 2) isolating the critical factors that determine 
how individual iNKT subsets are derived, with a focus on NKT2 cells (in 
chapter 3); 3) characterizing how distinct iNKT effector subsets specifically 
modulate protective host immune responses (in chapter 2 & 3); and 4) 
technical improvement in advancing more accurate analysis of ex vivo iNKT 
cells (in chapter 4).  
Firstly, in chapter 2, I demonstrate that the small proportion of thymic iNKT 
cells that express CCR7 represent a multi-potent progenitor pool that gives 
rise to effector subsets within the thymus. These CCR7+ iNKT cells also 
emigrate from the thymus in a Klf2 dependent manner, undergo further 
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maturation after reaching the periphery. Furthermore, Ccr7 deficiency 
impaired differentiation of iNKT effector subsets and localization to the 
medulla. Parabiosis and intra-thymic transfer showed that thymic NKT1 and 
NKT17 were resident-they were not derived from and did not contribute to the 
peripheral pool. Finally, each thymic iNKT effector subset produces distinct 
factors that influence T cell development.  
Secondly, previous studies showed IL-4 is produced by NKT2 cells in the 
thymus, where it conditions CD8+ T cells to become “memory like” amongst 
other effects in the steady state. However, the signals that cause NKT2 cells 
to constitutively produce IL-4 remain poorly defined, where in the chapter 3, 
these signals were investigated. Using histocytometry, IL-4 producing NKT2 
cells were localized to the thymic medulla, suggesting medullary signals might 
instruct NKT2 cells to produce IL-4. Moreover, NKT2 cells receive and require 
TCR stimulation for continuous IL-4 production at steady state, since NKT2 
cells lost IL-4 production when intra-thymically transferred into Cd1d deficient 
recipients. In bone marrow chimeric recipients, only hematopoietic, but not 
stromal APC, provided such stimulation. Furthermore, using different Cre-
recombinase transgenic mouse strains to specifically target CD1d deficiency 
to various APC, together with the use of diphtheria toxin receptor (DTR) 
transgenic mouse strains to deplete various APC, we found that macrophages 
were the predominant cell to stimulate NKT2 IL-4 production.  
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Lastly, it has been recently shown that high extracellular ATP concentrations 
or NAD-mediated P2RX7 ribosylation by the enzyme ARTC2.2 can induce 
P2RX7 pore formation and cell death. Because both ATP and NAD are 
released during tissue preparation for analysis, cell death through these 
pathways may compromise the analysis of iNKT. The expression of ARTC2.2 
and P2RX7 on distinct iNKT subsets is unclear, however, as is the impact of 
recovery from other nonlymphoid sites. Therefore, in the chapter 4, I showed 
NKT1 cells express high levels of both ARTC2.2 and P2RX7 compared with 
NKT2, NKT17 cells. Furthermore, I demonstrated that ARTC2.2 blockade 
enhanced NKT1 recovery from nonlymphoid tissues during cell preparation. 
Moreover, blockade of this pathway was essential to preserve functionality, 
viability, and proliferation of iNKT cells. Therefore, short-term in vivo blockade 
of the ARTC2.2/P2RX7 axis permits much improved flow cytometry–based 
phenotyping and enumeration of murine iNKT from nonlymphoid tissues, and 
it represents a crucial step for functional studies of this population. 
Altogether, I believe the findings here provide a clearer understanding of how 
the lipid specific iNKT cells become effector subsets as well as a technical 
improvement for accurate analysis of these cells. 
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Chapter 1 
Introduction 
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Natural killer T cells (NKT) were named because they express T cell receptor 
(TCR)–CD3 complexes as well as the natural killer (NK) cell receptor NK1.1 
(CD161) (1, 2). Later, research discovered that NKT cells express a semi-
invariant TCR, characterized by a Vα14-Jα18 TCRα chain coupled with a 
limited Vβ repertoire (Vβ2, Vβ7, or Vβ8.2) in mice, and an invariant Vα24-
Jα18 paired with Vβ11 in humans (3, 4). Owning to this semi-invariant TCR, 
invariant natural killer T (iNKT) cells recognize self- and foreign-lipid antigens 
presented by the CD1d molecule and could be specifically detected using 
CD1d tetramer loaded with a cognate lipid antigen. 
iNKT cells originate in the thymus, but in contrast to the conventional peptide 
specific CD4+ or CD8+ T cells, which are positively selected by cortical thymic 
epithelial cells, the positive selection of iNKT cells solely relies on the 
interactions among cortical double-positive (DP) thymocytes (5-8). DP 
thymocytes expressing the rearranged Vα14-Jα18 TCR recognize high-affinity 
lipid antigens presented by CD1d molecules on neighboring DP thymocytes 
(4). iNKT cells highly express the transcription factor promyelocytic leukemia 
zinc finger protein PLZF (zbtb46), which is essential for their effector program 
(9, 10), for specifying the tissue-resident properties of iNKT cells, and for their 
ability to produce cytokines early after stimulation (9-11). 
It has been realized that iNKT cells are a heterogenous population, and recent 
evidence from various groups suggest that there are three major functional 
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iNKT subsets at steady state according to their expression of lineage-specific 
transcription factors and cytokine-producing potential. The three iNKT subsets 
are designated NKT1, NKT2, and NKT17, in analogy to the classical CD4 T 
helper lineages. NKT1 cells are PLZFlow T-bet+ and produce both IFN-γ and 
low amounts of IL-4 after stimulation. They express NK1.1 and other NK 
receptors and represent the subset that “NKT” cells were named after. NKT2 
and NKT17 cells, in contrast, do not express NK1.1. NKT2 cells are 
PLZFhigh and produce high amounts of IL-4 at steady state and after 
stimulation. NKT17 cells are PLZFintermediate ROR-γt+ and produce IL-17 after 
stimulation (12). Through intra-thymic transfer and fetal thymic organ culture 
(FTOC), previous studies demonstrated that each iNKT subset (NKT1, NKT2, 
and NKT17) is terminally differentiated; i.e., do not give rise to other cell 
subsets (12-14). iNKT cells play diverse roles in immunity due in part to the 
existence of these three functional subsets. 
The Development and Differentiation of iNKT Cells 
Initial Positive Selection 
Like the conventional CD4+ and CD8+ T cells, iNKT cells originate from 
precursors undergoing TCR gene rearrangement in the thymus. A lineage 
tracing study using transgenic mice (ROR-γt–Cre × ROSA26lsl-EGFP) in 
which ROR-γt triggers permanent expression of green fluorescent protein 
(GFP) confirmed that iNKT cells were derived from ROR-γt+ DP thymocytes in 
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the thymus (5) (Figure 1-1 “Selection”), while a minor population could arise 
from DN thymocytes bypassing DP stage (15). Moreover, ROR-γt itself is 
essential for iNKT cell generation, in that, it supports DP survival through 
regulating Bcl-xL expression, allowing for optimal rearrangement of Vα14-
Jα18 TCR chains (16). Similarly, an E protein transcription factor, HEB, 
promotes survival of DP thymocytes through regulating both ROR-γt and Bcl-
xL expression, which opens the window of time to allow distal Jα 
rearrangement (17). Downstream of the initial selection of DP thymocytes, c-
Myc has been shown to control the maturation of iNKT cells (18, 19). 
Moreover, c-Myb has also been shown to play a central role in this process, 
as it supports long half-life of DP thymocytes to allow Vα14 to Jα 
rearrangement (20). 
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Figure 1-1. The selection, specification, and effector differentiation of invariant natural 
killer T (iNKT) cells in the thymus. The initial positive selection of iNKT cells depends on 
the interaction among double-positive thymocytes in cortex. Then, with the upregulation of 
PLZF and the chemokine receptor CCR7, the multi-potent iNKT common precursors migrate 
to thymic medulla and specify their fate into different effector subsets. The effector 
differentiation into NKT1, NKT2, and NKT17 are influenced and directed by various factors. 
For instance, cytokine signals play essential roles in differentiation: IL-15 is critical for CD122 
expressing NKT1 cell differentiation, whereas TGF-β is required for TGF-βR-expressing 
NKT17 cells, while NKT2 cells express IL-17 RB (IL-25 receptor), although the role of IL-25 
requires evaluation. iNKT subsets are poised in an effector state, but only NKT2 cells are 
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actively producing cytokine (IL-4) at steady state, while NKT1 and NKT17 cells maintain 
potential to produce IFN-γ or IL-17, respectively, after stimulation. 
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Immediate post-selection precursor iNKT cells are characterized as CD1d 
tetramer+ CD44− CD24+ CD69+, termed as “stage 0” iNKT cells. The strong 
TCR signal during iNKT selection was directly demonstrated using a reporter 
mouse in which a GFP cassette was inserted in the Nur77 locus (an 
immediate-early gene upregulated by TCR stimulation), wherein the GFP level 
indicates the TCR signal strength (21). In these mice, stage 0 iNKT cells 
express a high level of GFP indicating they received strong TCR signal during 
selection (21). Beside this strong TCR signal, the development of iNKT cells 
also relies on a “second signal” generated through homotypic interactions 
between signaling lymphocyte activation molecule family (SLAMF) receptors, 
SLAMF1 and SLAMF2, expressed on the DP thymocytes (22). In addition to 
supporting a long half-life in DP thymocytes, c-Myb also promotes the 
expression of CD1d and SLAMFs, which are essential for positive selection of 
iNKT cells (20). Deficiency of c-Myb completely abrogates the generation of 
iNKT cells, as CD24+ stage 0 iNKT cells were NOT detected (20). 
Historically, in B6 mice, the maturation of iNKT cells beyond stage 0 was 
described as a stepwise linear model from stage 1 to 3 based on expression 
of CD44 and NK1.1. In this model, the stage 0 iNKT cells develop into 
CD24− CD44− NK1.1− stage 1 cells, then upregulate CD44 to become stage 2 
cells, and finally acquire NK1.1 expression to become stage 3 cells in a linear 
fashion (23). This model fits some but not all the available data. For example, 
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NKT17 cells were known to express CD44 but not NK1.1 (stage 2), never 
become NK1.1+ (stage 3) (13). Alternatively, based on the expression of 
transcription factors, PLZF, Gata3, T-bet, and ROR-γt, CD24− iNKT cells could 
be very well categorized into three distinct subsets, NKT1, NKT2, and NKT17 
as described above. Similar to NKT17 cells, intra-thymic transfer of “stage 2” 
IL-4 producing NKT2 cells (IL-4+ IL-17RB+ CD4+) showed that they do not give 
rise to T-bet+ NK1.1+ “stage 3” cells either (12). Therefore, a revised lineage-
diversification model for iNKT cell development, in which a common 
progenitor gives rise to the distinct lineages of NKT1, NKT2, and NKT17 cells 
(Figure 1-1) was suggested. We herein discuss the promoting and inhibitory 
factors for selection, specification, and differentiation of iNKT cells, which are 
summarized in Table 1-1. 
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Table 1-1. Genetic factors influence development of iNKT subsets.  
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Specification 
Stage 0 iNKT cells arise from DP thymocytes in the thymic cortex (6). 
However, in CD1d tetramer-based immunofluorescence and histocytometric 
analysis, thymic iNKT subsets were found to be predominantly localized in the 
thymic medulla (24) (Figure 1-1). Consistent with this, the thymic medullary 
environment was reported to impact the functional maturation of iNKT cells 
(25). Therefore, the nature and localization of the common progenitor that 
directly gives rise to distinct subsets is unclear. Furthermore, the signals that 
drive their migration from cortex to medulla, as well as the medullary factors 
that control the differentiation of iNKT subsets has not yet been reported. A 
previous study demonstrated that the chemokine receptor CCR7, which 
responds to the chemokines CCL21, is important for thymocytes trafficking 
from the cortex to the medulla (26). Additionally, the number of iNKT cells was 
significantly reduced in CCR7−/− mice (27). Interestingly, single cell RNA-seq 
analysis of thymic iNKT cells suggested that PLZFhigh iNKT cells might 
comprise a progenitor population (28). Previous work showed IL-
4− PLZFhigh iNKT cells could further differentiate into T-bet+ NKT1 cells when 
sorted and intra-thymically transferred into thymus (12), suggesting they 
maintain precursor potential. Further analysis of this IL-4− PLZFhiiNKT cell 
population by RNA-seq and PCA analysis confirmed they have the least 
similarity to the three effector subset (29). Taken together, it could be inferred 
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that CCR7+ cells within PLZFhigh iNKT cells might serve as the common 
progenitor for iNKT subsets (Figure 1-1 “Specification”). 
Factors Involved in Specification and/or Effector Differentiation 
Cytokines 
IL-15, TGF-β, and IL-25 
Numerous studies have demonstrated cytokines produced in the local 
environment play central roles in determining the differentiation of CD4+ T 
helper subsets (Th1, Th2, and Th17) (30). Similarly, the differentiation of iNKT 
subsets is heavily influenced by different cytokine signals (Figure 1-1 “Effector 
differentiation”). For instance, it’s been shown that NKT1 cells highly express 
CD122 (IL2Rβ), and CD122-mediated IL-15 signaling is essential for the 
differentiation of NKT1 cells (31). Likewise, the absence of TGF-β signaling 
(CD4-Cre × TGF-βRIIflox/flox and CD4-Cre × Smad4flox/flox) led to complete loss 
of ROR-t+ NKT17 cells (32). Both NKT2 and NKT17 cells express IL-17RB 
(IL-25 receptor), which was essential for the production of IL-13, IL-9, IL-10, 
and IL-17 after stimulation with αGalCer (14), demonstrating that the cytokine 
production of activated iNKT cells is influenced by a signal through this 
receptor. It was further shown that such effect was dependent on E4BP4, a 
transcription factor that regulates IL-10 and IL-13 production in CD4+ T and 
iNKT cells (33, 34). Interestingly, E4BP4 seems to be upregulated in iNKT 
cells only after stimulation with IL-25 or αGalCer (14, 34), but not expressed 
12 
 
by thymic or most peripheral iNKT cells in the steady state (except the 
adipose iNKT cells) (14, 34, 35). Though inferred by the data, iNKT subsets 
defined by transcription factor expression as NKT1, 2, and 17 were not 
directly evaluated in the study (14). Thus, whether the development of NKT2 
and/or NKT17 cells is controlled by the IL-17RB/IL-25 axis remains or be 
defined. In a scenario where IL-25 signaling controls differentiation of NKT 
cells, it would be important to define the source of IL-25 in the thymus 
(Figure 1-1; Table 1-1). A recent study demonstrated that a type of specialized 
epithelial cells, called tuft cells, are the solely source of IL-25 in the gut (36). It 
will be interesting to check the thymus for this lineage of epithelial cells as 
well. 
Transcription Factors 
Egr2 
Strong TCR signaling in stage 0 iNKT cells commits their fate to iNKT lineage, 
as it leads to elevated expression of the transcription factors Egr1 and Egr2, 
which influence further development of iNKT cells (37). In agreement with 
Egr2 directly binding the PLZF promoter, Egr1 and Egr2 together are critical 
for PLZF induction, which indicates that Egr1 and Egr2 may be upstream of 
PLZF in determining iNKT lineage fate (37). In addition, Egr2-deficient iNKT 
cells failed to express CD122, indicating that elevated Egr2 expression not 
only specifies iNKT lineage at an early stage but its sustained expression may 
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also further influence differentiation of iNKT subsets (37). In addition, a 
cytoskeletal remodeling protein, P21-activated kinase 2 (Pak2) also influences 
the development of iNKT cells, especially NKT1 and NKT2 cells, possibly 
through regulation of the two critical transcription factors, Egr2 and PLZF (38). 
KLF Family Factors 
The transcription factor Kruppel-like factor 2 (KLF2) is essential for T cells 
egress from thymus and lymph node, because it’s required for the expression 
of sphingosine 1 phosphate receptor type 1 (S1P1) in T cells (39). 
Unexpectedly, thymocytes in KLF2-deficient mice (CD4-Cre × KLF2flox/flox) 
displayed a memory phenotype (CD44high CXCR3+ CD122+) that was shown 
to be an IL-4-dependent cell-nonautonomous effect (40). Furthermore, this 
effect was due to the expansion of IL-4-producing PLZFhigh T cells (mostly 
NKT2 cells), showing that KLF2 negatively regulates the differentiation of 
NKT2 cells (41). Another member of the Kruppel-like family, KLF13, plays the 
opposite role. KLF13 deficiency (KLF13−/−) led to a diminished population of 
IL-4-producing PLZFhigh iNKT cells (42). 
Hobit 
Though serving as an important factor that instructs the tissue retention 
program in iNKT cells and resident memory T cells (Trm) (43), the 
transcription factor Hobit was also shown to regulate the differentiation of 
iNKT cells (44). Hobit expression is high in CD44high NK1.1+ iNKT cells (mostly 
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NKT1 cells), but low in CD44low NK1.1− and CD44high NK1.1− iNKT cells 
(mostly NKT17 and NKT2 cells) (44). Accordingly, the number of 
CD44high NK1.1+ iNKT cells was significantly reduced in Hobit-deficient mice, 
while the abundance of CD44low NK1.1− and CD44high NK1.1− iNKT cells 
remained intact (44). Though the iNKT subsets were not distinguished in the 
study, it could be inferred from the data that Hobit promotes the differentiation 
and/or thymic retention of NKT1 cells. 
Lymphoid Enhancer Factor 1 (LEF1) and T Cell Factor 1 (TCF1) 
The transcription factors LEF1 and TCF1 are essential for T cell development 
including early commitment to the T cell fate, transition from DN to the DP 
thymocytes, as well as following CD4/CD8 choice (45). The critical role of 
LEF1 and TCF1 in the differentiation of iNKT subsets has also been shown. 
Deletion of TCF1 at DP stage (CD4-Cre × Tcf7flox/flox) led to a severe defect in 
all three iNKT subsets (46). In addition, iNKT cell development was similarly 
impaired in absence of LEF1 (Vav-Cre × Lef1flox/flox) (47). LEF1 was required 
for the proliferation and survival of iNKT cells, especially the massive 
expansion after stage 0 (47). Interestingly, though it influenced the 
development of all three iNKT subsets, LEF1 showed a preference in 
promoting the differentiation of NKT2 cells (47). 
Chromatin Modifiers 
Epigenetic modifications also regulate development and differentiation of iNKT 
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cells. The TET-family dioxygenases, TET1, TET2, and TET3, oxidize 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which is an 
important DNA modification critical for various biological processes (48-50). 
Simultaneous deletion of Tet2 and Tet3 resulted in uncontrolled TCR-
mediated expansion of NKT17 cells through suppression of T-bet and ThPOK 
(51). Jarid2, a component of polycomb repressive complex 2 that methylates 
histone 3 lysine 27 (H3K27), is also involved in iNKT cells development. 
Upregulated after TCR stimulation, Jarid2 directly binds to the PLZF promotor 
as a transcriptional repressor. Therefore, deficiency of Jarid2 led to significant 
expansion of PLZFhigh NKT2 cells (52). In addition, the transcriptional 
repressor NKAP was shown to be required for the development of iNKT cells, 
as the iNKT development was completely abrogated at stage 0 in mice 
deficient of NKAP (CD4-Cre × NKAPflox/flox) (53). How NKAP regulates iNKT 
cell development is not clear, but its interaction with the histone deacetylase 3 
(Hdac3) may be important, as NKAP is known to associate with Hdac3 and a 
similar defect of iNKT cells was observed in Hdac 3 conditional knockout mice 
(CD4-Cre × Hdac3flox/flox) (54). A recent report demonstrated that the 
H3K27me3 histone demethylase UTX is essential for iNKT cell development, 
especially the differentiation of NKT1 cells, as there was considerably fewer T-
bet+ NKT1 cells in UTX-deficient mice while NKT2 and NKT17 cells were not 
affected (55). UTX not only directly binds to the promoters of T-bet and CD122 
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genes but also influences the epigenetic landscape and transcription of PLZF-
activated genes (55). 
MicroRNAs (miRNAs) 
MicroRNAs are small noncoding single-strand RNAs (~22 nt) that modulate 
the stability and transcriptional activities of messenger RNAs (mRNAs) 
and via this mechanism influence the transcriptomes of various cells, leading 
to further effects on cellular proliferation, apoptosis, lineage commitment, and 
differentiation (56). Perhaps not surprisingly, complete loss of mature iNKT 
cells was observed in mice lacking Dicer (CD4-Cre × Dicerflox/flox), which are 
incapable of generating functional miRNAs in T cells, thus demonstrating that 
miRNAs are essential for the development of iNKT cells (57). miR-181a is 
abundant in DP thymocytes and could augment TCR signaling 
strength via enhancing the basal activation of TCR signaling molecules, such 
as increased basal phosphorylation level of Lck and ERK (58). Deletion of 
miR-181a (miR-181a/b-1−/− mice) completely blocked iNKT cell development 
at the DP/Stage 0, which was presumably due to reduced responsiveness to 
TCR signals as exogenous agonistic ligand (αGalCer) could rescue iNKT cell 
generation (59). The miR-17–92 family cluster is also critical for the 
development of iNKT cells, in that absence of miRNAs of the miR-17–92 
family cluster (triple knockout of three paralogs miR-17–92, miR-106a–363, 
and miR-106b–25 clusters) resulted in almost complete ablation of the three 
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iNKT effector subsets (60). Excessive TGF-β signaling was seen in the 
remaining triple knockout iNKT cells, but it did not solely account for the 
impaired iNKT cell development, because deletion of TGF-βRII did not fully 
restore the hemostasis of iNKT cells (60). It was further found that the Let-7 
family miRNAs, the most abundant family of miRNAs in mammals, tightly 
controls the differentiation of iNKT subsets (61, 62). Let-7 miRNAs are 
abundant in NKT1 cells while low in NKT2 and NKT17 cells, 
targeting Zbtb46 mRNAs and inhibiting PLZF expression, therefore, directing 
iNKT cell differentiation into PLZFlowNKT1 lineage (62). Moreover, Lin28 
inversely regulates Let-7 miRNAs, and Lin28 transgenic mice, which are 
practically deficient in Let-7 miRNAs, showed significantly increased NKT2 
and NKT17 cells (62). miR-150 is expressed in lymphocytes (B, T, and NK 
cells) and has been implicated in their maturation. Correspondingly, miR-150 
expression is expressed in iNKT cells after stage 0 (63, 64). In a mixed bone 
marrow chimera system, cell-intrinsic deficiency of miR-150 mildly affected 
iNKT cell development (63, 64), while overexpression of miR-150 substantially 
blocked maturation of iNKT cells beyond stage 0 (63). This suggests that fine-
tuning of miR-150 level might be critical for iNKT cell development. Though 
the molecular pathway underlying this miR-150-dependent iNKT cell 
development is unclear, regulation of c-Myb by miR-150 could be involved 
(63, 64). 
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Cellular Protein Degradation System 
While playing a central role in iNKT cell development, PLZF is initially induced 
in the stage 0 iNKT cells, and its expression can be regulated by the 
transcription factor Runx1 through direct binding to a critical enhancer of 
PLZF gene (65). Using Chip-Seq analysis, PLZF was shown to bind and 
regulate multiple genes, especially a broad set of immune effector genes 
expressed in iNKT cells (66). Beside directly regulating the expression of 
various genes, PLZF was also shown to transport an E3 ubiquitin ligase, cullin 
3 (CUL3), from cytosol to nucleus, which would induce unique and essential 
ubiquitination patterns in iNKT cells (67). The number of iNKT cells was 
dramatically decreased in mice lacking CUL3 (CD4-Cre × CUL3flox/flox), further 
substantiating the importance of PLZF–CUL3 interaction in the development 
of iNKT cells (67). In line with its association with CUL3, PLZF has also been 
reported to interact with enhancer of zeste homolog 2 (Ezh2) 
methyltransferase (68). Moreover, Ezh2 directly methylates PLZF, causing its 
ubiquitination and subsequent degradation. Deletion of Ezh2 leads to 
sustained expression of PLZF and substantial expansion of 
PLZFhigh NK1.1− iNKT cells (mostly IL-4-producing NKT2 cells) (68). 
Endogenous Selecting Lipid-Ligand and TCR Specificity 
The generation of iNKT cells depends on recognition of lipid antigen 
presented by CD1d molecules on DP thymocytes. This antigen is most likely 
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to be a self-lipid(s), because iNKT cells emerge early in life (6, 69), before 
stable colonization of commensal bacterial. Moreover, the phenotype and 
function of thymic and most peripheral iNKT cells (except pulmonary and 
intestinal iNKT cells) are normal in germ-free mice (70, 71). Regulated lipid 
metabolism in DP thymocytes is critical for thymic selection of iNKT cells, and 
the transcription factor Bcl11b plays a vital role in this process (72). Bcl11b-
deficient (CD4-Cre × Bcl11bflox/flox) thymocytes showed deficient presentation 
of endogenous lipid antigens, dysregulated endo-lysosomal compartment, 
and alterations in genes involved in lipid metabolism (72). Moreover, in a 
mixed bone marrow chimera system, Bcl11b-deficient DP thymocytes (TCR-
α−/−/CD4-Cre × Bcl11bflox/flox) failed to support selection of iNKT precursors in 
Bcl11b-sufficient DP thymocytes (β2m−/−/Bcl11b-Wt) (72). CD1d molecules 
can traffic between cell membrane and cytosolic organelles, surveying the 
endo-lysosomal compartment (73). A mouse model that expresses CD1d with 
a truncated cytoplasmic tail showed a severe defect in intracellular trafficking, 
and the number of iNKT cells was significantly reduced, suggesting the 
selection of iNKT cells relies on endosomal trafficking of CD1d molecule (74). 
Though a great effort has been made to understand the stimulatory thymic 
self lipid(s), controversy remains, as reviewed elsewhere (23, 75, 76). Briefly, 
iGb3, an endogenous lysosomal glycosphingolipid, though thought to be 
presented by LPS-activated dendritic cells that activate iNKT cells (77), is 
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unlikely to be a major selecting ligand for iNKT cells given that the 
development and function of iNKT cells are normal in 
isoglobotrihexosylceramide (iGb3)-deficient mice (78). Instead, 
glycosphingolipids (GSL) have been implicated in the development of iNKT 
cells as mice deficient of GSL-synthesizing enzyme glucosylceramide 
(GlcCer) synthase (GSC) in hematopoietic cells (Vav-Cre × GCSflox/flox) 
showed mild reduction of iNKT cells in both thymus and periphery (79). While 
stage 0 iNKT cells were not examined in the study, it remains unclear whether 
GSL are involved in the positive selection of iNKT cells. A recent report 
demonstrated the selecting ligands likely to be α-linked glycosylceramides 
(80). Since all glycosylceramides in mammals were believed to be β-anomers 
due to that mammalian glycosylceramide synthases are β-transferases (81), 
this finding is somewhat surprising. Earlier studies pioneered by the Brenner 
group showed, though initially thought to be a potent lipid self-antigen for 
iNKT cells, that β-glucopyranosylceramide (β-GlcCer) actually does NOT 
possess antigenic activity to iNKT cells (82, 83). The observed activity of β-
GlcCer is likely due to inclusion of an α-GlcCer species (83). These 
observations suggested the possibility that α-glycolipids are endogenous 
antigenic lipids for iNKT cells (83). However, nuclear magnetic resonance 
spectroscopy analysis at the time did not render a definitive identity (83). It is 
possible that an unknown alternative enzymatic pathway, unfaithful enzymatic 
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activities, or unique stressed cellular environments could confer production of 
small amounts of α-linked glycolipids, though the exact mechanism remain to 
be discovered (80, 84). The peroxisome-derived ether lipids seem to be 
partially involved in the iNKT cell development, as mice deficient in the 
peroxisomal enzyme glyceronephosphate O-acyltransferase (GNPAT) harbor 
moderately reduced iNKT cells and GNPAT−/− thymocytes are unable to 
support maturation of iNKT cells (85). However, the number of stage 0 iNKT 
cells are NOT changed in GNPAT−/− mice (85), suggesting that peroxisome-
derived lipids may not be the predominant selecting ligands for iNKT cells, but 
rather influence later developmental events of iNKT cells. The lysosomal 
phospholipase A2 (LPLA2), which modifies lysophospholipids in the 
lysosome, has been shown to play a role in thymic selection of iNKT cells, as 
both CD1d endogenous antigen presentation and iNKT cell numbers were 
negatively affected in the absence of LPLA2 (86). Taken together, considering 
that maturation of iNKT cells after positive selection of stage 0 iNKT cells 
requires the presence of CD1d in the thymus (87), it is possible that the 
endogenous lipid ligands for iNKT cells are presented in both thymic cortex 
and medulla and are displayed by different antigen-presenting cells (APCs). In 
this fashion, they may influence both selection (in the cortex) and effector 
differentiation (in the medulla) of iNKT cells (Figure 1-2). 
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Figure 1-2. The invariant natural killer T (iNKT) effector subsets modulate immune 
homeostasis in the thymic medulla. The iNKT effector subsets predominantly reside in the 
thymic medullary area. Both NKT2 and NKT17 cells express RANK ligand, which interacts 
with RANK on medullary thymic epithelial (mTEC) to induce Aire expression. NKT2 cells also 
produce IL-4 at steady state, which has a striking effect on CD8+ single positive thymocytes—
causing them to upregulate Eomes and adopt memory-like phenotype and function. The 
iNKT-derived type 2 cytokines, IL-4 and IL-13, also influence mTEC to promote emigration of 
mature thymocytes, through and as-yet undefined mechanism. The activation requirements 
for NKT2 cells are poorly defined, although they do need T cell receptor stimulation to 
produce IL-4 in the medulla. 
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Consistent with a potential role of specific self-lipids in effector differentiation, 
it was noted that the three iNKT subsets express distinct but stable Vβ 
repertoires (12, 88, 89). For example, NKT2 cells show a higher usage of Vβ7 
(12). Thus, a few studies have raised the hypothesis that differential TCR 
signaling events due to biased TCR Vβ gene usage could impact the 
differentiation of iNKT subsets (88, 89). Through generation of retrogenic mice 
expressing different CDR3β to manipulate iNKT TCR β chain in vivo, a recent 
study clearly demonstrated the half-life of TCR-Ag-CD1d interaction governs 
the frequency of different iNKT subsets in a cell-intrinsic manner. The number 
of NKT2 cells strongly correlated with the t1/2 of tetramer binding (90). As 
mentioned above, a high level of Nur77GFP was seen in NKT2 cells in the 
steady state, suggesting continuous TCR signaling in NKT2 cells (12). 
However, it is less clear whether such continuous TCR stimulation is required 
for the steady-state production of IL-4 in NKT2 cells and/or the development 
of PLZFhigh NKT2 cells (Figure 1-2). Since NKT2 cells reside in the thymic 
medulla, further efforts are required to elucidate where and how TCR binding 
kinetics of NKT2 cells might control their differentiation (Figure 1-2). 
iNKT Cells Modulate Tissue Homeostasis 
Major Role of iNKT-Derived IL-4 
Thymus 
Using KN2 mice, in which a human CD2 cassette was knocked into the IL-4 
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gene locus, and human CD2 expression on cell surface indicates active 
secretion of IL-4, a previous study demonstrated that thymic NKT2 cells 
produce abundant IL-4 at steady state (12). Another group showed thymic 
iNKT cells may also produce IL-13 at steady state in IL-13GFP mice (91). 
Because iNKT cells are predominantly localized in the medulla, IL-4 produced 
by NKT2 cells could influence a variety of immune events in that environment 
(Figure 1-2). Indeed, steady-state production of IL-4 selectively activates 
STAT6 in medullary CD8+ single-positive thymocytes, which drives them to 
become memory phenotype (CXCR3+ CD122+ Eomes+) (12, 41). This 
population of IL-4-induced memory T cells has been categorized as innate 
memory T cells (92), and they maintain greater function compared to naïve 
CD8+ T cells. They are well equipped to produce IFN-γ in response to TCR 
stimulation and showed much better expansion after infection with listeria 
monocytes (LM) (41). Moreover, the developmental exposure to IL-4 is critical 
for CD8+ T cells to mount robust Th1 responses to acute or chronic 
lymphocytic choriomeningitis virus infection (93, 94). Therefore, innate 
memory T cells are beneficial to the host for their functional superiority (95). 
Nevertheless, we do not yet understand, in the bigger picture, why iNKT cells 
recognition of medullary self-lipids should control this process. 
IL-4 impacts other immune cells beyond CD8 T cells in thymic medulla. A 
recent study demonstrated that the type 2 cytokines (IL-4/13) produced by 
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iNKT cells could influence in the thymic emigration of mature thymocytes (91). 
IL-4Rα−/− mice showed accumulation of mature T cell in the thymus and 
reduced recent thymic emigrants in the periphery (91). Medullary thymic 
epithelial (mTEC) cells express IL-4Rα and can respond to the type 2 
cytokines, as pSTAT6 level went up in mTEC of FTOC when IL-4 and IL-13 
were added in the culture (91). Moreover, disorganization of the thymic 
medulla was observed in mice deficient of IL-4Rα, that the medulla contained 
some epithelial-free areas revealed by the ERTR5 staining (91). It was 
speculated that IL-4/13 signaling in mTEC might promote the egress of 
mature T cells from thymus, though the specific mechanism remains to be 
uncovered (91). While the S1p–S1p1 axis remains intact in the IL-4Rα−/− mice 
(91), it is possible that the IL-4/13 produced by NKT2 cells serve as a novel 
regulator of thymic emigration of T cells. 
Periphery 
In the periphery, iNKT cells are critical for restoring homeostasis under 
stressed conditions. The regulatory role of iNKT cells has been implicated in 
the type 1 diabetes, where iNKT cells are less frequent and biased toward 
Th1 cytokine production in diabetic siblings than in their non-diabetic siblings 
(96). The protective role of iNKT cells has been shown in the mouse model for 
type 1 diabetes [non-obese diabetes (NOD) mouse], as CD1d−/− NOD mice, 
lacking iNKT cells, have a higher risk and earlier onsets of diabetes compared 
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to CD1d+/+ counterparts (97). Such protection is dependent on the IL-4 
production by iNKT cells (98, 99), and activation of iNKT cells to produce IL-4 
by cognate lipid antigen α-Galcer prevents diabetes in NOD mice (100, 101). 
Recent studies highlighted the key role of iNKT cells in regulating the 
pathogenesis of graft-versus-host disease (GvHD), a severe immunological 
dysregulation that frequently occurs after allogeneic hematopoietic stem cell 
transplantation (102, 103). Higher frequency of iNKT cells in patients 
correlated with lower risk of GvHD (103). In murine studies, stimulation with α-
Galcer or adoptive transfer of iNKT cells confer substantial protection against 
GvHD (104, 105). Furthermore, the iNKT cell-derived IL-4 and following 
regulatory T cells expansion seem to be critical for optimal suppression of 
GvHD (103-105). These data point iNKT cells as promising therapeutic 
regimen for GvHD patients. 
Invariant natural killer T cells are rare in most peripheral sites (0.1–1% of 
lymphocytes), but highly enriched in the liver, representing nearly 30% of 
hepatic lymphocytes (24). They are actively involved in restoring tissue 
homeostasis after sterile liver injury as demonstrated in a recent report (106). 
Shown by intravital microscopy, iNKT cells randomly patrol the sinusoids 
within liver in the steady state, while they rapidly move toward the injury site 
after injury (106, 107). Arrested at the injury site due to TCR stimulation and 
IL-12/18 signals, iNKT cells produce IL-4 to promote a series of events that 
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are vital for optimal tissue repair, including increased proliferation of 
hepatocytes, the switch of monocyte subtypes from CCR2high CX3CR1low to 
CCR2low CX3CR1high, as well as reduced collagen deposition (106). 
Altogether, these studies demonstrated that iNKT cells are potent regulator in 
immunity, largely due to their ability to produce abundant cytokines. Most of 
the studies implicated iNKT cell-derived IL-4 as the critical factor in restoring 
tissue homeostasis. Therefore, to unleash the therapeutic potential of iNKT 
cells, it will be important to have better understanding of the underlying 
mechanisms, especially the relevant APCs and the precise stimulatory lipid 
antigens that activate iNKT cells to produce IL-4. 
Role of Other iNKT Subsets 
Invariant natural killer T cells also have strong potential to produce other 
cytokines (IFNγ by NKT1 and IL-17 by NKT17). However, the role of these 
subsets and cytokines on tissue homeostasis has not been deeply explored, 
although it should be noted that NKT17 are abundant in the lung. iNKT cells 
also express a variety of other stimulatory or inhibitory molecules; therefore, 
they might influence immune homeostasis through direct cell contact. One of 
the molecules expressed by iNKT cells is RANK ligand (RANKL) (25). Signals 
through tumor necrosis factor family receptors (TNFRSF) RANK promotes 
Aire expression in mTEC (108). While iNKT cells express RANKL, and 
Aire+ mTECs were significantly reduced in CD1d−/− mice (25). It strongly 
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suggests that iNKT cells could regulate the development of mTEC through 
direct cross-talk to induce RANK signals. Further RNA-Seq analysis 
demonstrates that only NKT2 and NKT17 cells highly express RANKL (29), 
suggesting that iNKT subsets may have unique effects in modulating tissue 
homeostasis in the thymus (Figure 1-2). 
Nevertheless, despite increasing knowledge of iNKT cell development and 
functions, crucial questions regarding iNKT biology remain. The 
developmental steps that drive NKT cells into functional distinct subsets have 
not been elucidated. In thesis research, I aim to address this question through 
investigation of the following aspects: (1) Is there a progenitor for iNKT 
subsets, and what is the characteristic of it if there is one? In chapter 2, I 
showed definitively that CCR7+ iNKT cells serve as multipotent precursors for 
three iNKT subsets in thymus and periphery. (2) What are the critical factors 
that determine how individual iNKT subsets are derived. In chapter 3, I 
focused on the differentiation of NKT2 cells in thymus because they are the 
major source of IL-4 in the steady state and help shape thymic development 
in myriad ways. In this chapter, I demonstrated that TCR signaling in NKT2 
cells stimulated by macrophages is required for the steady state IL-4 
production in NKT2 cells. (3) Whether and how tissue resident iNKT effector 
subsets regulate tissue homeostasis? Using a novel technique to visualize 
endogenous iNKT cells within the tissues, iNKT effector subsets showed 
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selective tissue distribution, predominantly localized in medulla in the thymus. 
In chapter 2 and 3 collectively, I showed iNKT subsets shape thymic 
development through distinct mechanisms. (4) During thesis research, I made 
an important discovery that short term in vivo ARTC2.2 blockade enhanced 
NKT1 recovery from nonlymphoid tissues during cell preparation and was 
essential to preserve functionality, viability, and proliferation of iNKT cells. 
These findings were described in detail in chapter 4, which is a technical 
improvement that permits much improved flow cytometry–based phenotyping 
and enumeration of murine iNKT cells from nonlymphoid tissues, and it 
represents a crucial step for functional studies of this population. 
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Chapter 2 
CCR7 defines a precursor for murine iNKT cells in thymus and periphery 
 
  
31 
 
Overview 
The precise steps of iNKT subset differentiation in the thymus and periphery 
have been controversial. We demonstrate here that the small proportion of 
thymic iNKT and mucosal associated invariant T cells that express CCR7 
represent a multi-potent progenitor pool that gives rise to effector subsets 
within the thymus. Using intra-thymic labeling, we also showed that 
CCR7+ iNKT cells emigrate from the thymus in a Klf2 dependent manner, and 
undergo further maturation after reaching the periphery. Ccr7 deficiency 
impaired differentiation of iNKT effector subsets and localization to the 
medulla. Parabiosis and intra-thymic transfer showed that thymic NKT1 and 
NKT17 were resident—they were not derived from and did not contribute to 
the peripheral pool. Finally, each thymic iNKT effector subset produces 
distinct factors that influence T cell development. Our findings demonstrate 
how the thymus is both a source of iNKT progenitors and a unique site of 
tissue dependent effector cell differentiation. 
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Introduction 
Invariant natural killer T (iNKT) cells are αβ T cells expressing semi-invariant T 
cell receptors (TCR) that respond to self-lipids or foreign-lipids presented by 
the MHC-I like antigen-presenting molecule CD1d (23). They are numerically 
less abundant than conventional peptide recognizing CD4 and CD8 T cells but 
profoundly important, secreting a variety of cytokines early after stimulation or 
in the steady state to influence immune responses and tissue homeostasis 
(12, 24, 109, 110). Previous work has demonstrated that despite being 
monospecific, iNKT cells display substantial functional heterogeneity (14, 32, 
111-115), being composed of three predominant effector subsets, NKT1, 
NKT2 and NKT17 according to the expression of key transcription factors and 
cytokine production (12, 116). For instance, NKT1 cells are T-bet+ PLZFlow and 
produce IFN-γ; NKT17 cells are ROR-γt+ PLZFint and produce IL-17; while 
NKT2 cells are PLZFhigh, and produce IL-4 (12, 116). Through the selective 
activation and distinct localization of various iNKT effector subsets, iNKT cells 
can modulate immune responses and tissue homeostasis in different fashions 
(24, 109, 117). iNKT cells are positively selected in the thymus, in response to 
agonist interactions with self-lipid/CD1d expressing double positive 
thymocytes (DP) in the thymic cortex (5, 8, 21). At this point the cells express 
a high level of CD24, and are considered the most immature, or ‘stage 0’. In 
contrast, matured functionally competent effector iNKT cells localize 
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predominantly in the thymic medulla (24), and thymic medullary epithelial cells 
impact their functional maturation (25). Nonetheless, the developmental steps 
from stage 0 iNKT cells to mature iNKT effector subsets have remained 
unclear. Previous work used CD44 and NK1.1 to define ‘stages’ of iNKT 
development. However, more recent work showed that these markers are 
heterogeneously expressed on the mature cytokine producing iNKT effector 
subsets (14, 32, 111-115). Therefore, the field lacks precise identification of an 
iNKT multipotent precursor cell. Previous work in our lab, using T-bet and IL-4 
reporter mice, identified T-bet+ NKT1, ROR-γt+ NKT17, and IL-4+ PLZFhi NKT2 
cells as terminally differentiated (12). However, IL-4− PLZFhi iNKT cells still 
retained precursor potential, and could convert to T-bet+ NKT1 cells in the 
thymus (12). These results suggest there is heterogeneity within the 
PLZFhi iNKT cell population, and led us to hypothesize that there exists a 
population of progenitor cells within the PLZFhi iNKT cells. Indeed, 
transcriptional profiling by RNA-Seq indicated IL-4− PLZFhi iNKT cells had low 
similarity with the three effector subsets, including IL-4 producing PLZFhi iNKT 
cells (29). Single cell RNA-Seq analysis from another group also suggested 
there might be a progenitor population within the PLZFhi iNKT cells (28). 
Here we identify a previously unknown sub-population of PLZFhi CCR7+ iNKT 
cells as precursors for all three iNKT effector subsets. CCR7+ iNKT cells 
efficiently emigrate from the thymus in a Klf2 dependent manner and then 
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undergo further maturation on site. However, some iNKT cells maintain 
residency in the thymus where they undergo differentiation without circulating. 
The thymic and peripheral pools of iNKT effector subsets do not exchange 
and therefore depend on CCR7+ iNKT cells for their establishment. In addition 
to marking the precursor pool, CCR7 also directs iNKT progenitor cells to 
localize to the thymic medulla and is required for differentiation of iNKT 
effector subsets. We further establish that thymic iNKT cells influence T cell 
development and thymic tissue homeostasis. 
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Results 
CCR7+ iNKT and MAIT cells are at an early stage of development and 
represent a precursor pool for effector subsets in the thymus 
To identify iNKT cells at an early stage of development in the thymus, we used 
mice that express green fluorescent protein (GFP) under the control of the 
recombination-activating gene 2 (Rag2) promoter via a bacterial artificial 
chromosome transgene (Rag2GFP), in which GFP expression indicates the 
‘age’ of cells (118, 119). We found most thymic iNKT cells 
were Rag2GFP negative, while a small proportion of iNKT cells 
express Rag2GFP (Figure 2-1 A). The iNKT cells with the highest GFP also 
express CD24 and high level of CD69, indicating they are stage 0 iNKT cells 
that are immediate after agonist selection (Figure 2-1 A). Since we identified 
CCR7 as a potential progenitor specific gene (29), and a small population of 
CCR7+ iNKT cells could be specifically detected (Figure 2-2 A), we further 
examined CCR7 expression in iNKT cells in Rag2GFP mice. CCR7+ iNKT cells 
expressed high to intermediate amounts of GFP, suggesting they are 
immature and recently derived from stage 0 iNKT cells (Figure 2-1 
A and Figure 2-2 A). Whereas, the Rag2GFP lowest cells (most mature) did not 
express CCR7 (Figure 2-1 A). According to the conventional ‘staging’ system 
of iNKT cells in B6 mice, CCR7+ iNKT cells were predominantly 
NK1.1– CD44lo (stage 1) but also included some NK1.1− CD44+ cells (stage 2) 
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(Figure 2-1 B), although most NK1.1− CD44+ (stage 2) cells were not 
CCR7+ as this gate mostly included functionally mature NKT2 and NKT17 
cells, and NKT1 cells were NK1.1+ CD44+ (stage 3) (Figure 2-1 B). 
Furthermore, most CCR7+ iNKT cells did not express T-bet, ROR-γt, IL-4 
(human CD2) (Figure 2-1 C). Rather, CCR7+ iNKT cells expressed abundant 
PLZF and LEF1 (Figure 2-1 C), which are both essential for iNKT cells 
development and proliferation (9, 10, 47). 
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Figure 2-1. Thymic CCR7+ iNKT and MAIT cells are at an early developmental stage and 
give rise to distinct effector subsets in the thymus. 
(A) Expression of Rag2GFP and CCR7 in thymic iNKT cells (TCR-β+ CD1d-PBS57+) (left 
column), and of CD24 (middle column) and CD69 (right column) on cells with different levels 
of Rag2GFP. Data are representative of 3 independent experiments with 3–4 mice in each. (B) 
Expression of NK1.1 and CD44 in thymic CCR7+ iNKT (black dots), IL-4+ (human CD2+) 
NKT2 (red dots), ROR-γt+ NKT17 (blue dots), T-bet+ NKT1 (green dots) cells together with 
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total thymic iNKT cells (grey dots). Numbers in quadrants indicate percent cells in each for 
CCR7+ iNKT (black dots), IL-4+ (human CD2+) NKT2 (red dots), ROR-γt+NKT17 (blue dots) 
and T-bet+ NKT1 (green dots) cells. Data are representative of 4 independent experiments 
with 2–3 mice in each. (C) Expression of T-bet, ROR-γt, huCD2, PLZF, LEF1, Egr2 and CD4 
with CCR7 in thymic iNKT cells (TCR-β+ CD1d-PBS57+ CD24–). Data are representative of 3 
independent experiments with 2–3 mice in each. Numbers in quadrants indicate percent cells 
in each (throughout). (D) Frequency of Ki67+ cells in each population of thymic iNKT cells. 
Data are pooled from three independent experiments with 2–3 mice in each. ****p<0.0001 
(one-way ANOVA, Tukey’s multiple comparisons test) Each symbol represents an individual 
mouse; small horizontal lines indicate the mean. (E) Expression of Tbx21GFP, ROR-γt and 
human CD2 in CCR7+ iNKT cells sorted from BALB/c Tbx21GFP KN2 mice before intra-thymic 
transfer (left column) or 5 days after transfer in the thymus of congenic BALB/c recipient mice 
(right column). (F) Frequency of Tbx21GFP+, ROR-γt+ or human CD2+cells in donor cells 
before or 5 days after intra-thymic transfer into the thymus of congenic BALB/c recipient mice. 
Each symbol represents an individual recipient mouse; small horizontal lines indicate the 
mean. (G) SPADE analysis of thymic iNKT cells from B6 KN2 mice supports that 
CCR7+ NKTp are a distinct lineage from the effector subsets, NKT1, NKT2 and NKT17. 
Representative figure shows differential expression of human CD2 in each population of iNKT 
cells. (H) CCR7 and PD-1 distinguish two cell populations (top row, right column) within 
PLZFhi iNKT cells (top row, left column), and expression of human CD2 and CD44 in 
CCR7+ NKTp (grey), NKT1 (green), NKT2 (red) and NKT17 (blue) are shown as overlays 
(bottom row). Data are representative of 3 independent experiments with 3 mice in each. (I) 
39 
 
Expression of Rag2GFP together with CCR7 (middle column) in thymic MAIT cells (far left 
column), and expression of CD24 and CD69 in CCR7+ and CCR7– MAIT cells with different 
level of Rag2GFP (far right two columns). Data are representative of 2 independent 
experiments with 3 mice in each. 
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Figure 2-2. Specific CCR7 staining in iNKT cells and gating strategy of iNKT subsets 
and CD4/CD8 profile of CCR7+ iNKT and CCR7+ MAIT cells. 
(A) Representative flowcytometry profile of CCR7 staining in thymic iNKT cells enriched 
from Ccr7−/−, Wt and Rag2GFP mouse. (B) Gating strategy to identify enriched thymic iNKT 
cells as well as various subpopulations of iNKT cells, stage 0 iNKT (heavy black line), 
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CCR7+ iNKT (grey polygon), NKT1 (green polygon), NKT2 (red polygon) and NKT17 cells 
(purple rectangle). (C) Representative staining of Ki67 in various subpopulations of iNKT 
cells, stage 0 iNKT (black), CCR7+ iNKT (grey), NKT1 (green), NKT2 (red) and NKT17 cells 
(purple). Data are representative of three independent experiments with 2–3 mice in each. (D) 
CD4/CD8 profile of thymic CCR7+ iNKT cells. Identification of CCR7+ cells in enriched thymic 
iNKT cells (left column), and CD4/CD8 profile of CCR7+ iNKT cells (black dots) relative to the 
total thymocytes (grey dots) from the same mouse (right column). Number indicates percent 
cells in each gate. (E) Expression of T-bet and ROR-γt with CCR7 in thymic MAIT cells (TCR-
β+ CD1d-PBS57+). Data are representative of 2 independent experiments with 2 mice in each. 
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Figure 2-3. Thymic CCR7+ iNKT cells are enriched at an early timepoint in busulfan 
induced BM chimera. 
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(A) Experimental scheme to generate busulfan induced bone marrow chimeras and evaluate 
iNKT phenotype. (B) Frequency of CD24+ CD44− stage 0 iNKT cells among total iNKT cells 
(TCR-β+ CD1d tet+) (top row) and expression of NK1.1 and CD44 in the CD24− iNKT cells 
(bottom row) in the thymus at indicated time point after bone marrow chimera induction. (C) 
Expression of CCR7, PLZF, CD44 and T-bet in donor derived iNKT, host derived iNKT and 
total CD8 SP cells in the thymus at indicated time point after bone marrow chimera induction. 
(D) Expression of Nur77GFP in Stage 0 iNKT cells (TCR-β+ CD1d tet+ CD44– CD24+), 
CCR7+ iNKT cells and CD8 SP thymocytes. Data are representative of 2 independent 
experiments with two mice in each. (E) Normalized gMFI of Nur77GFP in stage 0 iNKT and 
CCR7+ iNKT cells. Data are pooled from two independent experiments with two mice in 
each. ****p<0.0001 (unpaired two tailed t test). Each symbol represents an individual mouse; 
small horizontal lines indicate the mean. (F) Expression of Tbx21GFP, ROR-γt and human CD2 
in CCR7+ iNKT cells sorted from BALB/c Tbx21GFP or BALBc KN2 mice before intravenous 
injection (left column) or 5 days after injection of congenic BALB/c recipient mice, in the 
spleen (right column). (G) Frequency of Tbx21GFP+, ROR-γt+ or human CD2+ cells in donor 
derived iNKT cells before or 5 days after intravenous injection of congenic BALB/c recipient 
mice, in the spleen. Each symbol represents an individual recipient mouse; small horizontal 
lines indicate the mean. (H) SPADE analysis of thymic iNKT cells from B6 and BALB/c KN2 
mice shows CCR7+ NKTp is a distinct lineage from the effector subsets, NKT1, NKT2 and 
NKT17. Representative figure shows differential expression of T-bet, ROR-γt, PLZF, huCD2, 
CCR7, PD-1 and CD44 in each population of iNKT cells. 
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Figure 2-4. Ultrasound imaging guided intra-thymic injection. 
(A) Representative ultrasound image of mouse chest area, the thymus is outlined by white 
dotted line (left column), the red arrow indicates the needle tip in thymus before injection 
(middle column), after injection the red arrow indicates the injected NHS-biotin contained in 
the thymus (right column). (B) Representative flowcytometry profile and (C) frequency of 
biotinylated cells revealed by streptavidin-PE staining in various cell populations (iNKT, CD4 
SP, CD8 SP and total thymocytes) in the thymus 24 hr later after intra-thymic injection of PBS 
or NHS-biotin. Data are pooled from six independent experiments with 2–6 mice in each. ns, 
not significant, p>0.05 (one-way ANOVA). Each symbol represents an individual mouse; 
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Mean ± SD. (D) Representative flowcytometry profile of CD1d tetramer staining in thymocytes 
of Cd1d KO or Wt mouse received intra-thymic injection of PBS or NHS-biotin.  
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To confirm that the CCR7+ iNKT cells were at an early developmental stage, 
we sought to track a 'wave’ of developing iNKT cells using busulfan induced 
bone marrow chimeras (Figure 2-3 A). We showed that, within CD45.1+ donor 
derive CD1d tetramer+ iNKT cells, the immature CD24+ CD44− stage 0 iNKT 
cells were enriched at an early time point (4 weeks) and contracted at a later 
time point (5 weeks), while the NK1.1+ CD44+ mature iNKT cells were scarce 
at 4 weeks but abundant at 5 weeks (Figure 2-3 B), suggesting this approach 
tracks the developmental steps of iNKT cells. With this approach, CCR7+iNKT 
cells (with lower CD44 and T-bet) were abundant at the early time point (4 
weeks) after bone marrow introduction and decreased at the later time point 
(5 weeks) (with increased CD44 and T-bet) (Figure 2-3 C). 
As CCR7+ iNKT cells expressed a high level of LEF1 (Figure 2-1 C), a 
transcription factor that is essential for iNKT cells proliferation, we examined 
Ki67 expression. Most CCR7+ iNKT cells expressed Ki67 (>75%) compared to 
the three effector subsets or the stage 0 iNKT cells (Figure 2-1 D, Figure 2-2 
B, C), suggesting they are highly proliferative. Stage 0 iNKT cells received 
strong TCR signal during agonist selection which could be indicated by the 
level of Nr4a1using Nr4a1GFP mice (also known as Nur77GFP mice which will 
be used throughout the manuscript) (21). Highly proliferative as CCR7+ iNKT 
cells are, the Nur77GFP could be diluted were they not continuously receiving 
TCR stimulation. We showed CCR7+ iNKT cells had much lower level of 
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Nur77GFP than stage 0 iNKT cells (Figure 2-3 D, E). A previous study 
suggested that the transcription factor Egr2 controls the development of iNKT 
cells and is highly expressed in iNKT thymic precursors (37). Consistently, we 
observed a high expression of Egr2 in CCR7+ iNKT cells while most thymic 
iNKT cells were positive for Egr2 expression (Figure 2-1 C). Moreover, 
consistent with a previous report that iNKT cells go through the CD4+ stage 
after stage 0 iNKT cells (6), we showed CCR7+ iNKT cells indeed exclusively 
expressed CD4, but not CD8 (Figure 2-1 C, Figure 2-2 D). 
These data raise the possibility that CCR7+ iNKT cells serve as progenitors for 
differentiation into effector subsets. We then directly assessed the potential of 
CCR7+ iNKT cells to develop into iNKT effector subsets by sorting 
CCR7+ thymocytes (CD4+ Tbx21GFP– huCD2– CD24– CD8–) 
from Tbx21GFP/KN2 mice and injecting them intra-thymically into congenic 
hosts. We used an ultrasound guided imaging technique to obtain accurate 
and efficient intra-thymic injection (Figure 2-4 A). Five days after intra-thymic 
transfer, all three effector subsets, NKT1, NKT2 and NKT17 cells were 
detected (Figure 2-1 E, F). To test the precursor potential of thymic 
CCR7+ iNKT cells in the periphery, we also injected the sorted 
CCR7+ thymocytes intravenously into congenic hosts and detected substantial 
differentiation of NKT1, NKT2 and NKT17 cells in the spleen (Figure 2-3 F, G), 
demonstrating that iNKT progenitors do not require the thymus for effector 
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differentiation. 
To better identify markers that can distinguish the precursor cells from 
cytokine producing NKT2 effector cells, we performed Spanning-tree 
Progression Analysis of Density-normalized Events (SPADE analysis) on total 
thymic iNKT cells based on a range of key transcription factors, surface 
markers and cytokines. Importantly, CCR7+ iNKT cells were clearly separated 
from the three major effector subsets, (Figure 2-1 G, Figure 2-3 H). Within the 
PLZFhi iNKT cells, CCR7 and PD-1 best distinguished progenitors from 
effectors, and only PLZFhi PD-1+ iNKT cells produced IL-4 (human CD2+) in 
the steady state (Figure 2-1 H). 
Previous reports suggested that the two lineages of innate-like T cells—iNKT 
cells and mucosal associated invariant T (MAIT) cells—have similarities in 
aspects of their phenotype and functions, such that developmental parallels 
might exist between the two (71, 120). Indeed, similar to CCR7+ iNKT cells 
(Figure 2-1 A), CCR7+ MAIT cells also had high to 
intermediate Rag2GFP expression while being low for CD24 and CD69 
expression, suggesting they are also at an early stage of development after 
agonist selection (Figure 2-1 I). Mature MAIT cells are composed of only two 
distinct effector subpopulations, ROR-γt+ and T-bet+ MAIT cells (71). 
CCR7+ MAIT cells did not express T-bet or ROR-γt (Figure 2-2 E). Together, 
these data suggest that both CCR7+iNKT cells and CCR7+ MAIT cells are 
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progenitor populations that give rise to their corresponding iNKT and MAIT 
effector cells. 
 
CCR7+ iNKT cells are the predominant emigrating iNKT cells and they 
depend on Klf2 for thymic emigration 
To investigate the phenotype of iNKT cells emigrating from the thymus, we 
performed intra-thymic injection of a biotinylating agent (NHS-biotin) to label 
thymocytes (Figure 2-4 A) and analyze peripheral lymphoid organs 24 hr later 
(Figure 2-5 A). This technique showed robust and unbiased labeling of nearly 
50% of all thymocytes (Figure 2-4 B, C) and did not interfere with the 
specificity of CD1d tetramer staining (Figure 2-4 D). Due to the low frequency 
of recent thymic emigrants (RTE) amongst total peripheral T lymphocytes 
(118, 119), we performed magnetic enrichment of biotin+ cells in the spleen. 
These two techniques combined offers a tool to accurately detect RTEs in 
periphery, as biotin+splenic CD4+ or CD8+ T cells are 
predominantly Rag2GFP+ (Figure 2-6 A, B). Using this tool, recent thymic 
emigrant iNKT cells (called 'RTE iNKT’) could be readily detected (Figure 2-5 
A), while biotin− iNKT cells within the unbound fraction are largely (>97%) ‘old’ 
iNKT cells—those cells already residing in the periphery before intra-thymic 
labeling (Figure 2-5 A). As expected, the RTE iNKT cells have 
higher Rag2GFP compared to biotin− iNKT cells (Figure 2-6 C). We further 
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found that RTE iNKT cells were highly enriched for CCR7+ cells compared to 
thymic or biotin− iNKT cells (Figure 2-5 B). Moreover, within the RTE iNKT 
cells, the CCR7+ cells expressed higher Rag2GFP than CCR7– cells (Figure 2-
6 D). In agreement with these data, Rag2GFP+ splenic iNKT cells were 
predominantly CCR7+, while most Rag2GFP– splenic iNKT cells did not express 
CCR7 (Figure 2-6 E). 
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Figure 2-5. CCR7+ iNKT cells are enriched in the emigrating iNKT population and 
depend on Klf2. 
(A) Experimental scheme to track recent thymic emigrants (RTE) through intra-thymic 
injection of NHS-biotin (left column) followed by enrichment of biotin+ splenic cells 24 hr after 
intra-thymic labeling, compared to ‘old’ cells (biotin– cells from spleen) (right column). (B) 
Expression of CCR7 in thymic, RTE and biotin− iNKT cells, the grey shade represents thymic 
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iNKT cells, the solid black line represents RTE iNKT cells, the dashed black line represents 
biotin− iNKT cells (top row); frequency of CCR7+ cells in thymic, RTE and biotin− iNKT cells, 
the solid grey circle represents thymic iNKT cells, the open circle represents RTE iNKT cells, 
the open square represents biotin− iNKT cells (bottom row). Data are pooled from 5 
independent experiments with 3–6 mice in each. ****p<0.0001 (one-way ANOVA) Each symbol 
represents an individual mouse; small horizontal lines indicate the mean. (C) Mixed bone 
marrow chimeras were generated with 25:75 ratio of donor bone marrow cells using 
CD45.2+ CD45.2+ B6 Klf2cKO cells and CD45.1+ CD45.2+ B6 Wt cells, or with 50:50 ratio of 
donor bone marrow cells using CD45.2+ CD45.2+ B6 Wt cells and CD45.1+ CD45.2+ B6 Wt 
cells. Eight weeks later, chimeras received intra-thymic labeling with NHS-biotin to track RTE 
among CD4, CD8 and iNKT cells. Data are representative of 2 independent experiments with 
4–8 mice in each. (D) Statistical analysis of thymic, RTE and biotin− CD4 T cells, CD8 T cells 
and iNKT cells in 8-week-old BM chimeras reconstituted with Klf2cKO and Wt cells (top row) 
or with Wt and Wt cells (bottom row). Data are pooled form 2 independent experiments with 
4–8 mice in each. Numbers indicate the ratio between the cells derived from each donor 
source. ****p<0.0001 (one-way ANOVA). ns, not significant, p>0.05 (one-way ANOVA). Each 
symbol represents an individual mouse; small horizontal lines indicate the mean. (E) 
Expression of Klf2GFP in CCR7+ iNKT, stage 0 iNKT, CCR7– iNKT cells and CD8 SP cells (top 
row). Normalized gMFI of Klf2GFP in CCR7+ iNKT, stage 0 iNKT, CCR7– iNKT cells (bottom 
row). Data are pooled from 2 independent experiments with 2 mice in each. ****p<0.0001 (one-
way ANOVA). Each symbol represents an individual mouse; small horizontal lines indicate the 
mean. 
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Figure 2-6. Intra-thymic labeling with NHS-biotin to identify RTEs in the periphery 
and Rag2GFP+ splenic iNKT cells are CCR7+. 
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(A) Gating strategy to identify RTEs of CD4 and CD8 T cells in spleen. (B) Expression 
of Rag2GFP in RTE CD4 or CD8 T cells, total splenic CD4 or CD8 T cells, and Wt total splenic 
CD4 or CD8 T cells. Data are representative of two independent experiments with three mice 
in each (C) Normalized Rag2GFP gMFI of RTE iNKT cells and biotin− iNKT cells in spleen. 
Data are pooled from two independent experiments with three mice in each. **p=0.0025 
(unpaired two tailed t test). Each symbol represents an individual mouse; small horizontal 
lines indicate the mean. (D) Normalized Rag2GFP gMFI of CCR7+ RTE iNKT cells and 
CCR7− RTE iNKT cells in spleen. Data are pooled from two independent experiments with 
three mice in each ***p=0.0006 (unpaired two tailed t test). Each symbol represents an 
individual mouse; small horizontal lines indicate the mean. (E) Rag2GFP+ iNKT cells 
predominantly express CCR7 (right column) when identified in spleen from B6 Rag2GFP mice 
(left column), green shade indicates Rag2GFP+iNKT cells and black line 
indicates Rag2GFP– iNKT cells. 
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Figure 2-7. RTE iNKT cells express high level of Klf2GFP. 
(A) Normalized Klf2GFP gMFI of RTE iNKT cells and biotin− iNKT cells. Data are pooled from 
two independent experiments with 2–4 mice in each. ****p<0.0001 (unpaired two tailed t test). 
Each symbol represents an individual mouse; small horizontal lines indicate the mean. 
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The transcription factor Kruppel-like factor 2 (Klf2) is crucial for the thymic 
egress of conventional CD4 and CD8 lymphocytes (39). However, its role in 
thymic emigration of iNKT cells is currently unknown. To test whether thymic 
egress of iNKT cells was dependent on Klf2, we analyzed mixed bone-marrow 
chimeras with wild type and Klf2-deficient bone marrow. We performed intra-
thymic labeling to track RTE. As expected, Klf2-deficient conventional CD4 
and CD8 T cells were enriched in the thymus and underrepresented amongst 
peripheral cells (Figure 2-5 C, D). Similarly, Klf2-deficient iNKT cells were also 
enriched in the thymus and underrepresented amongst RTE and biotin− iNKT 
cells populations (Figure 2-5 C, D), suggesting thymic emigration of iNKT cells 
is dependent on Klf2. As Klf2 regulates expression of S1PR1 (39), this is 
consistent with the previously reported requirement for S1PR1 in iNKT cell 
thymic egress (121). Next, we sought to assess Klf2 expression in thymic and 
RTE iNKT cells using Klf2GFP reporter mice. The majority of thymic iNKT cells 
did not express Klf2, though thymic CCR7+ iNKT cells or RTE iNKT cells 
highly expressed Klf2comparable to mature thymic CD8 single positive (SP) 
thymocytes or RTE CD8 T cells, respectively (Figure 2-5 E, Figure 2-7 A). 
Altogether, these results suggest that CCR7+ iNKT cells are the predominant 
thymic emigrating iNKT cell, and they do so in a Klf2 dependent manner. 
 
RTE iNKT are functionally immature and undergo further differentiation 
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in the periphery 
In further characterizing RTE iNKT cells, we observed that T-bet+, and ROR-
γt+ cells were substantially underrepresented amongst RTE iNKT cells 
compared to total thymic iNKT cells (Figure 2-8 A, B), suggesting that both T-
bet+ NKT1 and ROR-γt+NKT17 cells may be resident in the thymus. This is 
consistent with the previously reported long-term retention of thymic 
NK1.1+ iNKT cells (122). Similarly, thymic NKT2 cells that produce high levels 
of IL-4 (human CD2) were also less likely to be found amongst RTE (Figure 2-
8 B). Though CCR7+ iNKT cells were predominant within the RTE population, 
a small proportion of T-bet+ NKT1 cells were still observed (Figure 2-8 A, B). 
However, cells within this small population failed to express Qa2, while the 
thymic T-bet+ NKT1 and splenic biotin− T-bet+NKT1 cells both expressed high 
level of Qa2 (Figure 2-8 C, D). As Qa2 has commonly been used to mark the 
most mature thymocytes, this suggests that RTE NKT1 cells were recently 
derived from progenitors, as opposed to emigrating as a mature cell. Indeed, 
in cells collected 72 hr after intra-thymic labeling, we observed a progressive 
increase in Qa2 in RTE NKT1 cells (Figure 2-8 C, D). Furthermore, RTE T-
bet+ NKT1 expressed significantly higher PLZF at 24 hr, while the expression 
was down regulated over 72 hr (Figure 2-8 D). Taken together, these results 
strongly suggested that RTE T-bet+ NKT1 cells were not directly derived from 
mature thymic NKT1 cells, but more likely recently differentiated from 
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precursors. To further support this hypothesis, we sorted CCR7+ thymocytes 
(CD4+ Tbx21GFP– huCD2–CD24– CD8–) from Tbx21GFP/KN2 mice and injected 
them intra-thymically into congenic hosts (Figure 2-9 A). Five days later, all 
three effector subsets, NKT1, NKT2 and NKT17 cells were detected in the 
spleen (Figure 2-9 B, C), indicating CCR7+ iNKT cells rapidly emigrate to the 
periphery and serve as precursors that give rise to iNKT effector subsets. 
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Figure 2-8. RTE iNKT cells are immature and undergo further differentiation after 
reaching periphery. 
(A) Expression of T-bet and ROR-γt in thymic, RTE and splenic biotin− iNKT cells. Number in 
quadrants indicates percent cells in each (throughout). Data are representative of 3 
independent experiments with 2–6 mice in each. (B) Frequency of T-bet+ NKT1, ROR-
γt+ NKT17 cells and normalized gMFI of IL-4 (human CD2) in thymic, RTE and 
splenic biotin− iNKT cells. The solid grey circle represents thymic iNKT cell, the open circle 
represents RTE iNKT cells, the open square represents biotin− iNKT 
cells. **p=0.0048, ****p<0.0001 (one-way ANOVA). Data are pooled from 3 independent 
experiments with 2–6 mice in each. Each symbol represents an individual mouse; small 
horizontal lines indicate the mean. (C) Expression of Qa2 in thymic, 24 hr RTE, 72 hr RTE 
and splenic biotin− T-bet+ NKT1 cells. Data are representative of 3 independent experiments 
with 2–3 mice in each. (D) Normalized gMFI of Qa2 in thymic, 24 hr RTE, 72 hr RTE and 
biotin− T-bet+ NKT1 cells (left column). Normalized gMFI of PLZF in thymic, 24 hr RTE, 72 hr 
RTE and splenic biotin− T-bet+ NKT1 cells (right column). ****p<0.0001 (one-way ANOVA). 
Data are pooled from 3 independent experiments with 2–3 mice in each. Each symbol 
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represents an individual mouse; small horizontal lines indicate the mean. 
 
 
Figure 2-9. Thymic CCR7+ iNKT emigrate to the periphery and undergo further 
development into effector subsets. 
(A) Experimental scheme for intra-thymic transfer of sorted CCR7+ thymocytes 
(CD4+ Tbx21GFP–huCD2– CD24– CD8–) from Tbx21GFP/KN2 mice into congenic hosts. The 
phenotype of donor derived iNKT cells was examined in the spleen after 5 days. (B) 
Expression of Tbx21GFP, ROR-γt and human CD2 in CCR7+ iNKT cells sorted from 
BALB/c Tbx21GFP KN2 mice before intra-thymic transfer (left column) or 5 days after transfer 
into congenic BALB/c recipient mice (right column). (C) Frequency of Tbx21GFP+, ROR-γt+ or 
human CD2+ cells in donor cells recovered in the spleen, before or 5 days after intra-thymic 
transfer into the thymus of congenic BALB/c recipient mice. Each symbol represents an 
individual recipient mouse; small horizontal lines indicate the mean. 
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Ccr7 deficiency impairs differentiation of iNKT effector subsets and their 
localization to the thymic medulla 
As CCR7+ iNKT cells serve as progenitors for all three subsets of iNKT cells in 
the thymus, we sought to evaluate whether CCR7 itself might regulate the 
differentiation of thymic iNKT cells. To test this, we created mixed bone-
marrow chimeras with wild type and Ccr7-deficient bone marrow cells, and 
analyzed the phenotype of thymic iNKT cells derived from both donors. As 
expected, the generation of double positive (DP) thymocytes was not affected 
by the absence of CCR7, while iNKT cells derived from the Ccr7-deficient 
donors showed substantially impaired differentiation of all three iNKT effector 
subsets (Figure 2-10 A, B). Similar to CCR7+ iNKT cells, CCR7+ MAIT cells 
were at early stage of development (Figure 2-1 I) and distinct from effector 
MAIT cells (Figure 2-2 E), which suggested the possibility of a similarly 
important role of CCR7 in the development of MAIT cells. In mixed bone 
marrow chimeras with wild type and Ccr7-deficient bone marrow cells, MAIT 
cell differentiation was also severely impaired when lacking cell-intrinsic CCR7 
(Figure 2-11 A–C). 
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Figure 2-10. Ccr7 deficiency impairs iNKT subsets differentiation and medullary 
localization. 
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(A) Mixed bone marrow chimeras were generated with 50:50 ratio of donor bone marrow cells 
using CD45.2+ CD45.2+ B6 Ccr7 KO cells and CD45.1+ CD45.2+ B6 Wt cells, or with 50:50 
ratio of donor bone marrow cells using CD45.2+ CD45.2+ B6 Wt cells and 
CD45.1+ CD45.2+ B6 Wt cells. Eight weeks later, the frequency of thymic iNKT effector 
subsets and thymocytes derived from different donor source were analyzed. Data are 
representative of 3 independent experiments with 4–10 mice in each. Numbers adjacent to 
outlined areas indicate percent cells in each, throughout. (B) Statistical analysis of thymic 
iNKT subsets and DP thymocytes in 8-week-old BM chimeras reconstituted with Ccr7 KO and 
Wt cells or with Wt and Wt cells. Numbers indicate the ratio between the cells derived from 
each donor source. ***p=0.0001 (unpaired two tailed t test). ****p<0.0001 (unpaired two 
tailed t test). ns, not significant, p>0.05 (unpaired two tailed t test). Data are pooled from 3 
independent experiments with 4–10 mice in each. Each symbol represents an individual 
mouse; small horizontal lines indicate the mean. (C) Thymic sections of Cd1d KO (left 
column) and Wt (right column) B6 mice were stained with CD1d tetramer (red) and the DNA-
binding dye DAPI (grey) to visualize iNKT cells in situ. (D) Thymic sections of BM chimeras 8 
weeks after reconstituted with Ccr7 KO and Wt cells were stained for the cortical-thymic-
epithelial-cell-associated proteasomal subunit β5t (blue), CD1d tetramer (red), CD45.1 
(green) and the DNA-binding dye DAPI (grey) to visualize and distinguish cortex, medulla, 
CD45.1−Ccr7 KO iNKT and CD45.1+ Wt iNKT cells. Yellow outline (middle column) indicates 
magnified area (right column); Arrows indicate CD45.1−Ccr7 KO iNKT cells (red), CD45.1+ Wt 
iNKT cells (yellow). C: Cortex; M: Medulla. (E) Flowcytometry analysis of thymocytes (left 
column), histocytometry analysis of immunofluorescence image (middle column) and 
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localization of CD45.1− Ccr7 KO iNKT cells (red dot), CD45.1+ Wt iNKT cells (yellow dot) as 
determined by histocytometry (right column). (F) Frequency of iNKT cells localized in thymic 
medulla from 8-week-old BM chimeras reconstituted with Ccr7 KO and Wt cells (left column) 
or with Wt and Wt cells (right column). *p=0.0141, ns, not significant, p=0.1775 (unpaired two 
tailed t test). Each symbol represents an individual mouse; small horizontal lines indicate the 
mean. 
 
 
Figure 2-11. Ccr7 deficiency impairs MAIT cells differentiation. 
(A) Gating strategy to identify enriched thymic MAIT cells and mature ROR-γt+ and T-
bet+ MAIT cells. (B) Mixed bone marrow chimeras were generated with a 50:50 ratio of donor 
bone marrow cells using CD45.2+ CD45.2+ B6 Ccr7 KO cells and CD45.1+ CD45.2+ B6 Wt 
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cells, or with 50:50 ratio of donor bone marrow cells using CD45.2+ CD45.2+ B6 Wt cells and 
CD45.1+ CD45.2+ B6 Wt cells. Seven weeks later, the frequency of thymic MAIT mature 
subsets and thymocytes derived from different donor source were analyzed. Numbers 
adjacent to outlined areas indicate percent cells in each throughout. Data are representative 
of 3 independent experiments with 2–6 mice in each. (C) Statistical analysis of thymic MAIT 
mature subsets and DP thymocytes in 7-week-old BM chimeras reconstituted with Ccr7 KO 
and Wt cells or with Wt and Wt cells. Numbers indicate the ratio between the cells derived 
from each donor source. Data are pooled from 3 independent experiments with 2–6 mice in 
each. ***p=0.0009 (unpaired two tailed t test). ****p<0.0001 (unpaired two tailed t test). ns, not 
significant, p>0.05 (unpaired two tailed t test). Each symbol represents an individual mouse; 
small horizontal lines indicate the mean. 
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It was recently shown that CCR7 responds to CCL21a produced in the thymic 
medulla and is essential for migration of thymocytes from the cortex to 
medulla (26). To directly assess whether CCR7 directs the medullary 
localization of thymic iNKT cells, we performed CD1d tetramer based 
immunofluorescence and histocytometry analysis in the mixed bone-marrow 
chimeras reconstituted with wild type and Ccr7-deficient bone marrow donors. 
CD1d tetramer based immunofluorescence could specifically detect the CD1d 
restricted iNKT cells in the thymus (Figure 2-10 C). Moreover, Ccr7-deficient 
iNKT cells showed significantly reduced localization in the thymic medulla 
compared to wild type iNKT cells (Figure 2-10 D–F). These data suggest that, 
CCR7 not only plays an indispensable role in differentiation of thymic iNKT 
effector subsets, but also directs iNKT cells to localize in thymic medulla. 
 
Thymic iNKT effector subsets are resident and influence thymic tissue 
homeostasis 
To gain insight into the potential tissue residency of thymic iNKT effector 
subsets, we generated parabiotic mice, which share blood circulation through 
surgical joining (Figure 2-12 A). Congenically distinct CD45.1+ and 
CD45.2+ mice were surgically connected for 30 days. Splenic CD4 or CD8 T 
cells were present at 50:50 ratios in parabiotic pairs consistent with their 
known circulation patterns (Figure 2-12 B, C). In contrast, ~80% of splenic 
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iNKT cells were of host origin (Figure 2-12 B, C), confirming that the majority 
of splenic iNKT cells are not circulating (11). Remarkably, >95% of thymic 
iNKT cells were of host origin (Figure 2-12 B, C). Considering that thymic 
iNKT effector subsets are negative for Rag2GFP (Figure 2-1 A), these data 
suggest that iNKT cells in the thymus are largely tissue-resident. 
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Figure 2-12. Thymic iNKT effector subsets are predominantly resident and may 
influence thymocytes maturation. 
(A) Experimental scheme of parabiosis surgery. (B) Representative flowcytometry profile of 
spleen and thymus from the CD45.2+ host of a parabiotic pair after 30 days of parabiosis 
surgery, the number indicates the frequency of CD45.2+ (host) and CD45.1+ (parabiotic 
counterpart) cells in CD8 T cells and iNKT cells. Numbers adjacent to outlined areas indicate 
percent cells in each throughout. Data are representative of 2 independent experiments with 3 
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parabiotic pairs in each. (C) The frequency of cells derived from the host parabiont in splenic 
CD4+ T, CD8+ T and iNKT cells as well as thymic iNKT cells. Data are pooled from 2 
independent experiments with 3 parabiotic pairs in each. ns, not significant, p=0.8722 (one-
way ANOVA). ***p=0.0009, ****p<0.0001 (one-way ANOVA). Each symbol represents an 
individual mouse; small horizontal lines indicate the mean. (D) CCR7+ Tbx21GFP– and 
CCR7– Tbx21GFP+thymocytes were sorted from BALB/c Tbx21GFP mice and intra-thymically 
transferred to congenic BALB/c recipients (left column). After 5 days, the donor derived iNKT 
cells were recovered in thymus and spleen from mice received CCR7+ Tbx21GFP– thymocytes 
or CCR7– Tbx21GFP+ thymocytes (right column). Numbers adjacent to outlined areas indicate 
percent cells in each throughout. Data are representative of 5 independent experiments. (E) 
Cell number of donor derived iNKT cells recovered in thymus and spleen from mice that 
received CCR7+ Tbx21GFP– thymocytes or CCR7– Tbx21GFP+thymocytes. Data are pooled 
from 5 independent experiments with 2 mice in each. ns, not significant, p=0.1508 (unpaired 
two tailed t test). **p=0.0079 (unpaired two tailed t test). Each symbol represents an individual 
mouse; small horizontal lines indicate the mean. (F). Expression of YFP in DP thymocytes 
(left column) or thymic NKT1 cells (NK1.1+ CD44+) (right column), the grey shade represents 
cells from Wt mice, the solid green line represents cells from Ifn-γYFP mice; Numbers adjacent 
to solid black line indicate percent of Ifn-γYFP+ cells from Ifn-γYFP mice; Data are representative 
of 4 independent experiments with 3–5 mice in each. (G) Frequency of Ifn-γYFP+ cells within 
thymic NKT1 cells. Data are pooled from 4 independent experiments with 3–5 mice in each. 
Each symbol represents an individual mouse; small horizontal lines indicate the mean. (H) 
Expression of Qa2 in CD4 SP or CD8 SP thymocytes from Wt or Cd1d KO mice. Numbers 
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adjacent to outlined areas indicate percent cells in each throughout. Data are representative 
of 5 independent experiments. (I) Frequency of Qa2+ cells in CD4 SP or CD8 SP thymocytes 
from Wt, Cd1d KO and Ifn-γRKO mice. Data are pooled from 5 independent experiments, 
n = 18 (Wt), n = 11 (Cd1d KO), n = 6 (Ifn-γRKO). *p=0.0426, **p=0.0023, ****p<0.0001 (one-way 
ANOVA). ns, not significant, p=0.2676 (CD4 SP), p=0.8848 (CD8 SP) (one-way ANOVA). 
Each symbol represents an individual mouse; small horizontal lines indicate the mean. (J) 
Expression of RankL in thymic NKT1, NKT2 and NKT17 cells (upper panel). Normalized gMFI 
of RANKL in thymic NKT1, NKT2 and NKT17 cells (bottom panel). Data are representative of 
3 independent experiments with 2–3 mice in each. **p=0.0027 (NKT1 vs NKT2), *p=0.0391 
(NKT1 vs NKT17) (one-way ANOVA). (K) Expression of Aire in TEC from Wt, Cd1d KO or Aire 
KO mice. Numbers adjacent to outlined areas indicate percent cells in each throughout. Data 
are representative of 4 independent experiments. (L) Frequency and number of Aire+ mTEC 
(left and middle column), number of total TEC (right column) from Wt and Cd1d KO mice. 
Data are representative of 4 independent experiments, n = 5 (Wt), n = 6 
(Cd1d KO). ****p<0.0001, **p=0.0032, ns, not significant, p=0.5209 (unpaired two tailed t test). 
Each symbol represents an individual mouse; small horizontal lines indicate the mean. 
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Figure 2-13. NKT1 and NKT17 cells do not rely exclusively on CD69 or CD103 for tissue 
residency. 
(A) Expression of CD69 (left column) and CD103 (right column) in thymic PLZFhi iNKT cells, 
NKT17 cells, NKT1 cells and DP thymocytes. (B) Expression of CD69 in thymic NKT1 cells 
from Cd69+/+, Cd69+/– and Cd69–/– mice. (C) Number of NKT1 cells in thymus (left column) 
and spleen (right column) from Cd69+/+, Cd69+/– and Cd69–/– mice. Data are pooled from 3 
independent experiments, n = 6 (Cd69+/+), n = 5 (Cd69+/–), n = 4 (Cd69–/–). ns, not 
significant, p>0.05 (one-way ANOVA). Each symbol represents an individual mouse; small 
horizontal lines indicate the mean. (D) Experimental scheme for blocking CD103 and E-
cadherin interaction in thymus. BALB/c mice were intra-thymically injected with CD103 and E-
cadherin blocking antibodies or isotype control antibody every other day (at day 0, day 2 and 
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day 4), mice received intra-thymic labeling with NHS-biotin at day six and enrich biotin+ cells 
in spleen to track RTE 24 hr later. (E) CD103 staining in thymic PLZFhi iNKT cells, NKT17 
cells, NKT1 cells and CD8 SP thymocytes from mice received isotype control antibody (left 
column) or blocking antibodies (right column). (F) Frequency of NKT17 cells among thymic, 
RTE and biotin− iNKT cells from mice received isotype control antibody (circle) or blocking 
antibodies (square). Data are pooled from 2 independent experiments, n = 7 (isotype), n = 6 
(blocking mAbs). ns, not significant, p>0.05 (unpaired two tailed ttest). Each symbol 
represents an individual mouse; small horizontal lines indicate the mean. 
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We also directly tested the retention or emigration of sorted thymic 
CCR7+ iNKT cells (CD4+ Tbx21GFP– CD24– CD8–) or Tbx21GFP+ NKT1 
(CCR7– CD24– CD8–) cells by transferring them intra-thymically into congenic 
hosts. In contrast to thymic CCR7+iNKT cells, wherein a substantial number of 
transferred cells were recovered from spleen 5 days after transfer, the 
transferred Tbx21GFP+ NKT1 cells were rarely recovered from spleen (Figure 
2-12 D, E), strongly suggest that CCR7+ iNKT cells efficiently emigrate thymus 
while iNKT effector subsets are retained in the thymus. Together, these results 
show that peripheral iNKT effector subsets are not directly derived from 
thymic iNKT effector subsets, but rather develop from the CCR7+iNKT 
progenitors, and indicate that thymic and peripheral pools of iNKT effector 
subsets do not exchange. 
Consistent with their tissue residency, NKT1 and NKT17 cells highly express 
the classical tissue residency molecules CD69 and CD103, respectively 
(Figure 2-13 A). To evaluate whether CD69 and CD103 are required for the 
thymic retention of NKT1 and NKT17 cells, we 
analyzed Cd69+/+, Cd69+/– and Cd69–/– mice. We observed comparable 
number of NKT1 cells among these mice in both thymus and spleen (Figure 
2-13 B, C). To block CD103 interaction with E-Cadherin on epithelial cells, 
monoclonal antibodies (mAb) against CD103 and E-Cadherin were intra-
thymically injected three times (Figure 2-13 D, E). Combined with intra-thymic 
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biotin labeling to track RTE iNKT, we did not observe loss of thymic NKT17 
cells nor increase of NKT17 cells in the RTE and peripheral iNKT cells 
population (Figure 2-13 F). These data indicate the thymic retention of iNKT 
effector subsets is unlikely to solely rely on either CD69 or CD103. 
That iNKT effector subsets are preferentially retained in the thymus raises the 
question of their function there. To ask whether NKT1 cells might have effects 
in the thymus, we investigated if they were producing IFN-γ in the steady state 
using IFN-γ reporter mice. We observed that ~50% of NKT1 (NK1.1+ CD44+) 
cells were Ifn-γYFP positive (Figure 2-12 F, G). Furthermore, Qa2 expression 
on mature thymocytes was recently shown to be interferon dependent (123), 
and was reduced in absence of iNKT cells (Figure 2-12 H, I), comparable to 
that observed in IFN-γ receptor-deficient mice (Figure 2-12 I), showing that 
the IFN-γ produced by NKT1 cells is biologically active, although the 
functional relevance remains unclear. Lastly, iNKT cells have been shown to 
regulate mTEC differentiation through the production of RANKL (25). We 
demonstrate here that NKT2 and NKT17 cells are the exclusive producers of 
RANKL among iNKT cells (Figure 2-12 J). Consistent with a previous report 
(25), the absence of iNKT cells resulted in specific reduction of Aire+ 
medullary thymic epithelial cells (mTEC), while the number of total TEC was 
not affected (Figure 2-12 K, L). Together these data strongly suggest iNKT 
cells modulate thymic homeostasis and indicate the possibility that they might 
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further influence T cell development. Given that different inbred strains have 
strikingly different ratios of iNKT effector subsets in the thymus, our data imply 
that retention of lipid specific effector T cells in the thymus fine-tunes T cell 
development and tissue homeostasis. 
 
Discussion 
Previously, PLZFhi iNKT cells have been defined as NKT2 cells, however, our 
data strongly suggested that CCR7+ PLZFhi iNKT cells had multi-lineage 
potential in both the thymus and periphery. Thus, PLZFhi iNKT cells comprise 
a mixture of progenitors and mature IL-4 producing NKT2 effector cells. Such 
heterogeneity was indicated in the previous RNA-Seq analysis of 'bulk 
PLZFhi NKT2 cells' (28, 29). Moreover, our data demonstrate that CCR7 not 
only marks the precursors but also directs iNKT cells to localize to the thymic 
medulla, which plays a critical role in their differentiation to effector subsets. 
This is consistent with a previous report, which showed that Ccr7 deficient 
mice harbor fewer thymic iNKT cells (27). Considering the predominant 
medullary localization of all three iNKT effector subsets (24), it would seem 
that medullary factors are crucial for the differentiation and/or 
maintenance/survival of iNKT effector subsets. Indeed, IL-15 derived from 
medullary thymic epithelial cells (mTEC) was implicated in the generation of T-
bet+ NKT1 cells (25, 124). Whether and how medullary factors are required for 
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differentiation of NKT2 and NKT17 cells remains to be determined. 
Another type of innate-like T cells, MAIT cells, which are restricted to MR1 
and recognize riboflavin metabolites, have gained interest recently. A number 
of studies indicated a parallel between these iNKT cells and innate-like T cells 
in their development and functions (71, 120, 125). For example, both mature 
iNKT and MAIT cells are poised effector cells, producing large amounts of 
cytokines upon stimulation; both express and depend on PLZF; and both are 
composed of effector subsets analogous to CD4 T helper subsets. We show 
here that, similar to iNKT cells, CCR7 also marks a population of immature 
MAIT cells after the agonist selection. However, whether CCR7 directs their 
localization remain to be answered. 
Mature iNKT effector subsets, including NKT1, NKT2 and NKT17, exist in both 
the thymus and peripheral tissues (24). Since iNKT cells originate in the 
thymus (5, 8), this raises the question whether the peripheral iNKT effector 
cells directly arise from mature thymic iNKT effector cells or not. Previous 
work showed that a thymic NK1.1− iNKT cell emigrates (69, 126), but the work 
was performed before it was appreciated that mature NKT2 and NKT17 
effector cells are also NK1.1−. In this study, we demonstrate that all thymic 
iNKT effector cells are long-term residents that do not emigrate, and that 
peripheral iNKT effector subsets derive from CCR7+ iNKT cells that emigrate 
from the thymus. iNKT cells can participate in immunity to infection (23), but 
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they can also regulate tissue homeostasis in the steady state (29, 35, 109, 
117). An effect of NKT2 cells on CD8 T cell development in the steady state is 
well supported by previous data showing their constitutive production of IL-4 
drives Eomesodermin (Eomes) expression and a memory-like functional state 
in CD8 T cells (12, 24). In this report, we further show that thymic resident 
NKT1 cells produce IFN-γ and promote Qa2 expression in CD4 and CD8 SP 
thymocytes. T cells up-regulate Qa2 expression during their maturation in the 
thymus, and type I interferon signaling has been implicated in this process 
(123). It is possible that IFN-γ might function synergistically with type I 
interferon to influence Qa2 expression. Lastly, we show both NKT2 and 
NKT17 cells express RANK ligand, and together could promote Aire 
expression in mTEC in supporting central tolerance. 
It is worth mentioning that a small number of CCR7+ iNKT cells express lower 
amounts of PLZF, LEF1 or CD4. Indeed, the development of iNKT cells in the 
thymus is a dynamic process, even though the CCR7+ iNKT cell population is 
largely immature and maintains precursor potential, it seems likely some of 
these cells have begun to receive development signals and to differentiate, 
prior to having completely lost CCR7 expression. Of interest, though CCR7 is 
critical for optimal differentiation of all three iNKT subsets, NKT17 cells seem 
to be most affected by CCR7 deficiency. Since NKT1, NKT2 and NKT17 are 
all localized to the thymic medulla, it is unclear what might cause this effect. 
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Possibly, the differentiation or maintenance of NKT17 cells is more dependent 
on as yet undefined factors in the medullary environment. 
In summary, we demonstrate here that the sub-population of CCR7+ 
PLZFhi iNKT cells represent a pool of precursor cells for all three iNKT effector 
subsets in thymus and periphery. Meanwhile, CCR7 not only marks the 
precursors, but also directs the medullary localization and differentiation of 
iNKT effector subsets. The thymic and peripheral iNKT effector subsets are 
resident and do not exchange, therefore depend on CCR7+ iNKT progenitors 
for their establishment. 
 
Material and Methods 
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Table 2-1 Key resources table 
Mice 
B6 (C57BL/6NCr) and B6.SJL (B6-LY5.2/Cr) mice were purchased from the 
Reagent type (species) or
resource
Designation Source or reference Identifiers
Additional
informatio
n
antibody anti-CCR7 BD Biosciences Cat # 562675 (1:50)
antibody anti-CD4 BD Biosciences Cat # 563331 (1:400)
antibody anti-CD8α BD Biosciences Cat # 563786 (1:400)
antibody anti-CD24 BioLegend Cat # 101824 (1:200)
antibody anti-NK1.1 BioLegend Cat # 108718 (1:100)
antibody anti-CD44 TONBO Biosciences Cat # 80-0441-U025 (1:200)
antibody anti-human CD2 BioLegend Cat # 309218 (1:20)
antibody anti-TCRβ BD Biosciences Cat # 563221 (1:200)
antibody anti‑PD-1 BioLegend Cat # 135213 (1:100)
antibody anti-CD45.1 BioLegend Cat # 110738 (1:200)
antibody anti-CD45.2 eBioscience Cat # 11-0454-81 (1:200)
antibody anti-Qa2 BioLegend Cat # 121710 (1:200)
antibody anti‑RANKL eBioscience Cat # 12-5952-82 (1:100)
antibody anti-B220 BioLegend Cat # 103244 (1:200)
antibody anti-CD11c eBioscience Cat # 47-0114-82 (1:200)
antibody anti-CD11b eBioscience Cat # 47-0112-82 (1:200)
antibody anti‑F4/80 eBioscience Cat # 47-4801-82 (1:200)
antibody anti-CD122 BD Biosciences Cat # 562960 (1:100)
antibody anti-PLZF BD Biosciences Cat # 563490 (1:200)
antibody anti-ROR-γt BD Biosciences Cat # 562684 (1:200)
antibody anti-T-bet BioLegend Cat # 644824 (1:200)
antibody anti-Egr2 eBioscience Cat # 17-6691-80 (1:100)
antibody anti-Aire eBioscience Cat # 50-5934-82 (1:100)
antibody anti-LEF1 Cell Signaling Technology Cat # 2230S (1:100)
antibody anti-Rabbit IgG AF488 Invitrogen Cat # A11034 (1:400)
antibody anti-IL-17RB R&D Systems Cat # FAB10402G (1:20)
antibody Goat-anti-R Phycoerythrin (PE) Abcam Cat # ab34721 (1:200)
antibody Donkey-anti-Goat AF555 Abcam Cat # ab150130 (1:400)
antibody Rabbit-anti-β5t MBL International Cat # PD021 (1:100)
antibody Goat-anti-Rabbit BV480 BD biosciences Cat # 564879 (1:400)
antibody anti-EpCAM BioLegend Cat # 118214 (1:200)
Other streptavidin-PE BD biosciences Cat # 554061 (1:400)
Other streptavidin-BV421 BioLegend Cat # 405225 (1:400)
Other Ulex Europaeus Agglutinin I (UEA I) VECTOR LOBORATORY FL-1061 (1:200)
commercial assay or kit Viability dye Ghost Dye™ Red 780 TONBO Biosciences Cat # 13-0865-T100 (1:500)
commercial assay or kit anti-biotin MACS beads Miltenyi Cat # 130-105-637
commercial assay or kit anti-PE microbeads Miltenyi Cat # 130-048-801
chemical compound, drug Bulsulfan MP Biomedicals Cat # 154906
chemical compound, drug Streptavidin Jackson ImmunoResearch Cat # 016-000-113
chemical compound, drug DNase I Roche Cat # 10104159001
chemical compound, drug Liberase TH Roche Cat # 5401127001
chemical compound, drug sulfo-NHS-LC biotin ThermoFisher Scientific Cat # 21335
software, algorithm SPADE CytoBank https://www.cytobank.org/
software, algorithm Prism 7 GraphPad https://www.graphpad.com/
software, algorithm ImageJ ImageJ https://imagej.nih.gov/ij/
software, algorithm
FlowJo v10 TreeStar - Flowjo
https://www.flowjo.com/solutions/flowj
o
Key Resources Table
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National Cancer Institute. BALB/c (BALB/cJ or BALB/cBYJ as indicated), 
congenic CD45.1+BALB/cBYJ (CByJ.SJL(B6)-Ptprca/J), CD4Cre B6, Ifn-
γYFP B6 (B6.129S4-Ifngtm3.1Lky/J), Ifn-γRKO B6 (B6.129S7-
Ifngr1tm1Agt/J), AireKO B6 (B6.129S2-Airetm1.1Doi/J), Ccr7KO B6 (B6.129P2(C)-
Ccr7tm1Rfor/J), Cd1d−/− B6 (B6.129S6-Cd1d1/Cd1d2tm1Spb/J) 
and Cd1d−/−BALB/c.J (C.129S2-Cd1tm1Gru/J) mice were obtained from the 
Jackson Laboratory. Rag2GFP B6, Klf2GFP B6, Klf2fl/fl B6, KN2 BALB/cBYJ and 
B6, Tbx21GFP Balb/cBYJ and Tbx21GFP KN2 BALB/cBYJ have been previously 
described (12, 24, 40, 119, 127). Cd69−/− B6 (Cd69 KO) mice were kindly 
provided by Dr. Linda Cauley at University of Connecticut Health Center. 
CD4Cre Klf2fl/fl (Klf2 cKO) mice were generated through crossbreeding at 
University of Minnesota. All animal work was conducted in compliance with 
the protocols approved by the Institutional Animal Care and Use Committee of 
the University of Minnesota. 
 
Flow cytometry and antibodies 
Single-cell suspensions were prepared from thymus and spleen. Biotinylated 
PBS57 loaded or unloaded CD1d monomers and MR1–5–OP–RU or control 
MR1–Ac–6–FP monomers were obtained from the tetramer core of the US 
National Institutes of Health and tetramerized with streptavidin-PE (invitrogen) 
or streptavidin-APC (invitrogen) at the ratio of 4:1. For staining of CCR7, cells 
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were stained with antibody to CCR7 (4B12, BD Biosciences) at 37°C for 45 
min. For intracellular staining of transcription factors, cells were stained with 
antibodies to surface makers, then fixed and permealized with a Foxp3 
staining buffer set (eBioscience), and were incubated with antibodies to PLZF 
(R17-809, BD Biosciences), T-bet (4B10, Biolegend), ROR-γt (Q31-378, BD 
Biosciences), Egr2 (erongr2, eBioscience) or Aire (5H12, eBioscience). For 
staining of LEF1, fixed and permealized cells were incubated with antibody to 
LEF1 (C12A5, Cell Signaling Technology), followed by staining with 
secondary antibody to Rabbit IgG (A11034, Invitrogen). Antibody to mouse IL-
17RB was from R and D Systems (752101, rat IgG1). Ulex Europaeus 
Agglutinin I (UEA I) was from VECTOR LOBORATORY. Viability dye Ghost 
Dye Red 780 was from TONBO Biosciences. The complete list of other 
antibodies used is as follows and were purchased from eBioscience, BD 
Biosciences or BioLegend, unless otherwise indicated: anti-CD4 (GK1.5 or 
RM4-4), CD8α (53–6.7), anti-CD24 (M1/69), anti-NK1.1 (PK136), anti-CD44 
(IM7), anti-human CD2 (TS1/8 or RPA-2.10), anti-TCRβ (H57-597), anti-PD-1 
(29F.1A12), anti-CD45.1 (A20), anti-CD45.2 (104), anti-Qa2 (695H1-9-9), anti-
RANKL (IK22/5), anti-B220 (RA3-6B2), anti-CD11c (N418), anti-CD11b 
(M1/70), anti-F4/80 (BM8), anti-CD122 (TM-β1). See table 2-1 for a list of 
antibodies and reagents used in this stufy. Cells were analyzed on a BD LSR 
Fortessa or BD Fortessa X-20 and data were processed with FlowJo 
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software. 
 
Enrichment of iNKT cells or MAIT cells 
Single cell suspensions were prepared from thymus or spleen and incubated 
with PE-CD1d-PBS57 tetramer at 4°C or with PE-MR1–5–OP–RU tetramer at 
room temperature. Then anti-PE microbeads (Miltenyi) were used for 
immunomagnetic enrichment according to the manufacturer's instructions. 
 
SPADE analysis of thymic iNKT cells 
Thymic iNKT cells were enriched from B6 KN2 or BALB/c KN2 thymus. 
Enriched iNKT cells were stained with antibodies to CCR7, TCR-β, IL-17RB, 
CD1d tetramer, CD24, T-bet, PD-1, PLZF, CD44, Dump (viability dye, B220, 
F4/80, CD11c), CD8, ROR-γt, human CD2, CD4. Total thymic iNKT cells 
(TCR-β+ CD1d tetramer+ CD24–) were subjected to SPADE analysis on 
Cytobank (www.cytobank.org) based on expression of following surface 
markers, key transcription factors and IL-4 production: CCR7, IL-17RB, PD-1, 
CD44, CD4, T-bet, PLZF, ROR-γt, human CD2. 
 
Intra-thymic and intravenous injection 
Thymocytes from BALB/c KN2, BALB/c Tbx21GFP or BALB/c Tbx21GFP KN2 
mice were depleted of CD8+ and CD24+ cells (via immunomagnetic selection 
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[Miltenyi]) to enrich thymic iNKT cells. CCR7+ CD4+ human CD2–, 
CCR7+ Tbx21GFP–, CCR7+ CD4+Tbx21GFP– human CD2– cells or 
CCR7– Tbx21GFP+ cells were sorted with a FACSAria. Ultrasound imaging 
guided intra-thymic injections were performed on congenic host mice 
(BALB/c) using a Vevo 2100 preclinical scanner (VisualSonics) with a MS550 
transducer. Ultrasound guided intrathymic injection is described in detail at 
Bio-protocol (128). Mice received intra-thymic transfer or intravenous 
injections of cells were analyzed 5 days after injections. For intra-thymic 
injection of biotin to track RTEs, mice were given ~10 µL of 1 mg/mL solution 
of sulfo-NHS-LC biotin. At 24 hr or 74 hr later, biotin+ RTEs in spleen were 
enriched by immunomagnetic selection (via anti-biotin MACS beads 
[Miltenyi]), and stained with streptavidin-PE or streptavidin-BV421, followed by 
blocking with free streptavidin (Jackson ImmunoResearch) before staining for 
surface markers and CD1d tetramer. 
 
Bone marrow chimera 
Bone marrow cells were prepared from the femurs and tibias of donor mice, 
and depleted of T cells with CD90.2 MACS beads. Recipient mice 
(CD45.1+ CD45.1+) were lethally irradiated (2 × 500 rads) and received 
5 × 106 T-cell-depleted bone marrow cells. Mixed donor cells consisted of 
25% of Klf2 cKO cells (CD45.2+ CD45.2+) and 75% of Wt cells 
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(CD45.1+ CD45.2+) or 50% of Ccr7 KO cells (CD45.2+ CD45.2+) and 50% of 
Wt cells (CD45.1+ CD45.2+) or 50% of Wt cells (CD45.2+ CD45.2+) and 50% 
of Wt cells (CD45.1+ CD45.2+). All chimeras were analyzed 7 or 8 weeks after 
transplantation unless otherwise indicated. For busulfan induced bone marrow 
chimeras, recipient mice (CD45.2+ CD45.2+) were injected intraperitoneal with 
400 μg of busulfan on two consecutive days, and received 1 × 107 T-cell-
depleted bone marrow cells (CD45.1+ CD45.1+). Busulfan induced bone 
marrow chimeras were analyzed at 4 and 5 weeks after transplantation. 
 
Parabiosis surgery 
Parabiosis surgeries were performed as previously described (127). Briefly, 
mice were anesthetized with ketamine, and flank hair was shaved and further 
removed using Nair. After making lateral incisions, mice were joined with 
interrupted horizontal mattress sutures with 5–0 NOVAFIL. Additional sutures 
were placed through the olecranon and knee joints to secure the legs. 
Parabiotic pairs were analyzed 30 days after surgeries. 
 
Preparation of thymic epithelial cells 
The procedure for preparation of thymic epithelial cells have been previously 
described (129). Briefly, fresh thymus was digested with 0.05% [w/v] of 
Liberase TH (Roche) and 100 U/ml of DNase I (Roche) and mechanically 
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disrupted. After complete digestion, flowcytometic analysis was performed, 
and total thymic epithelial cells were identified as CD45– EpCAM+ cells. 
 
Immunofluorescence 
The CD1d tetramer immunofluorescence has been described previously (24). 
Briefly, fresh thymic lobes were incubated with PE-CD1d-PBS57 tetramer at 
4°C overnight. The tissues were then washed with PBS and fixed in 4% 
paraformaldehyde (PFA) for 1 hr and snap frozen in OCT. Five micrometer 
sections were made and stained with Goat-anti-R Phycoerythrin (PE) (Abcam) 
followed by Donkey-anti-Goat AF555 (Abcam). The sections were incubated 
with Rabbit-anti-β5t (MBL International) and anti-CD45.1 AF647 (Biolegend) 
at 4°C overnight, followed by Goat-anti-Rabbit BV480 (BD biosciences). The 
sections were counterstained with DAPI covered with Prolong anti-fade 
mounting medium (Life Technologies). The images were obtained with a Leica 
DM6000B Epi-Fluorescent microscope. 
 
Histocytometry 
The histocytometry analysis was described previously (24, 130). Briefly, the 
region of interests (ROIs) were identified and the fluorochrome intensities of 
each ROI were quantified using ImageJ and data were exported into Excel, 
Prism and FlowJo software for the localization analysis. 
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Ultrasound imaging guided intra-thymic injection 
The intra-thymic injection was guided by ultrasound imaging using the Vevo 
2100 preclinical scanner (VisualSonics) with the MS550 transducer, which 
ranges from 32 to 40 MHz. Briefly, we identified the thymus in the ultrasound 
imaging, then adjusted and slid the needle under the transducer until it could 
be clearly visualized above the skin of the chest area. The needle was then 
inserted into the thymus gland, approaching continuously toward the thymus 
area while avoiding penetrating any attached blood vessels or going 
underneath the aorta. Once the needle tip was observed within the thymic 
area, a 10 µL volume was injected. 
 
Statistical analysis 
Prism software (GraphPad) was used for statistical analysis. Unpaired or 
paired two-tailed t-tests, and one-way ANOVA were used for data analysis 
and calculation of p values. Data sets (in Prism format) are available per 
request. 
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Chapter 3 
Myeloid cells activate iNKT cells to produce IL-4 in the thymic medulla 
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Overview 
IL-4 is produced by a unique subset of invariant natural killer T (iNKT) cells 
(NKT2) in the thymus in the steady state, where it conditions CD8+ T cells to 
become “memory like” amongst other effects. However, the signals that cause 
NKT2 cells to constitutively produce IL-4 remain poorly defined. Using 
histocytometry, we observed that IL-4 producing NKT2 cells were localized to 
the thymic medulla, suggesting medullary signals might instruct NKT2 cells to 
produce IL-4. Moreover, NKT2 cells receive and require TCR stimulation for 
continuous IL-4 production at steady state, since NKT2 cells lost IL-4 
production when intra-thymically transferred into CD1d deficient recipients. In 
bone marrow chimeric recipients, only hematopoietic, but not stromal APC, 
provided such stimulation. Furthermore, using different Cre-recombinase 
transgenic mouse strains to specifically target CD1d deficiency to various 
APC, together with the use of diphtheria toxin receptor (DTR) transgenic 
mouse strains to deplete various APC, we found that macrophages were the 
predominant cell to stimulate NKT2 IL-4 production. Thus NKT2 cells appear 
to encounter and require different self-lipid ligands for selection in the cortex 
and activation in the medulla.  
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Introduction 
The thymus is a primary lymphoid organ that supports T cells development.  
Nonetheless, even in the steady state, cells of the thymus produce effector 
cytokines typically associated with acute immune responses, including type I 
interferon (IFN-α/β), type II cytokines (IL-4/13), and IFN-γ (12, 24, 40, 41, 91, 
123, 131-133). These steady state cytokines shape the thymic 
microenvironment in myriad ways, which affects T cell development and 
tolerance (12, 24, 40, 41, 91, 123, 131-133). In particular, steady state IL-4 in 
the thymus drives CD8+ single positive thymocytes to differentiate to a 
memory-like state through upregulation of eomesodermin (eomes) (12, 24, 
40, 41). These IL-4 exposed CD8 T cells display antigen receptor independent 
survival and effector function due to upregulation of CD122 and IL-12/18R 
(thus are often referred to as “innate CD8” T cells), and have trafficking 
properties similar to memory cells due to upregulation of chemokine receptor 
CXCR3 and CD44 (12, 24, 40, 41). Innate CD8+ T cells were shown to have 
superior function compared to naïve T cells (40, 41, 92-95) and are thought to 
play a critical role in defense against infections (40, 41, 92-95). Thymic steady 
state IL-4 also promotes the development and function of regulatory T cells 
(Tregs), particularly those that arise through the Foxp3low Treg progenitor 
pathway (134, 135). In addition, thymic dendritic cells (DC) are also 
influenced, secreting chemokines CCL17 and CCL22 in response to IL-4 
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signaling (12), which might further affect thymocyte-DC interactions in the 
organ. Furthermore, thymic B cells undergo class switch recombination, and 
this process is partially supported by thymic IL-4, as steady state IL-4 
promotes class switch into IgE and IgG1 (12)(data not shown). Finally, IL-4 
signaling in medullary thymic epithelial cells (mTEC) has been shown to 
promote the thymic emigration of mature T cells (91). Given all of these 
effects, it is of interest to understand how IL-4 production is driven in the 
thymus. 
 
Previous reports showed that steady state IL-4 in the thymus is largely 
produced by lipid-specific invariant natural killer T (iNKT) cells (12, 41). iNKT 
cells express a semi-invariant T cell receptor (TCR), characterized by Vα14-
Jα18 chains paired to a limited set of Vβ chains in mice (136). iNKT cells 
specifically recognize lipid antigens presented by the non-polymorphic MHC-
like molecule CD1d, which contrasts with conventional CD4+ or CD8+ T cells 
that recognize peptides presented by highly polymorphic MHC molecules 
(136). Recent reports showed that mature iNKT cells are composed of three 
major functionally distinct subsets, termed as NKT1, NKT2 and NKT17, 
according to their expression of transcription factors and cytokine responses 
upon activation, analogous to the CD4+ T helper sub-lineages (12, 136). In 
general, NKT1 cells are positive for T-bet and produce IFN-γ; NKT17 cells are 
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positive for ROR-γt and produce IL-17; while NKT2 cells express a high level 
of PLZF and produce IL-4. It is these PLZFhigh NKT2 cells that were shown to 
produce IL-4 in the thymus in the steady state (12, 24). Although “self” lipids 
are implicated in the positive selection of iNKT precursors by CD1d+ double 
positive (DP) thymocyte antigen presenting cells in the thymic cortex (5, 21, 
80), it is not known if iNKT cells continue to recognize or respond to self lipids 
as they differentiate. 
 
In this study, we sought to explore the factors that drive iNKT cells to produce 
IL-4 in the steady state. Secretion of cytokines by T cells is usually a result of 
activation by cytokine and/or TCR signaling, and the steady state IL-4 
production by iNKT cells in the thymus might very well fall into this scenario. 
Indeed, recent findings identified a specialized subset of medullary thymic 
epithelial cells (called thymic tuft cells), with striking similarity to peripheral 
mucosal tuft cells, which produce IL-25 to further stimulate the differentiation 
of NKT2 cells (36, 137). Here, we show that NKT2 cells predominantly reside 
in the thymic medulla. They receive and require TCR stimulation for their IL-4 
production in the steady state. Moreover, this TCR stimulation in NKT2 cells is 
solely mediated by CD1d expressed by hematopoietic antigen presenting 
cells (APC), and macrophages were the predominant cell that triggered the 
steady state IL-4 production by NKT2 cells. Collectively, our findings show 
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that NKT2 cells integrate TCR and cytokine signals for IL-4 production in the 
thymic medulla in the steady state. 
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Results 
NKT2 cells produce IL-4 in the steady state and are predominantly 
located in the thymic medulla 
To directly investigate the thymic cells that secrete IL-4 in the steady state, we 
used an IL-4 reporter mouse strain (KN2, wherein a human CD2 reporter 
gene was introduced into the endogenous Il-4 locus). In these mice, the IL-4 
protein secreting cells can be faithfully detected through the expression of 
human CD2 (huCD2) on the cell surface (138). In comparison to wild-type 
(Wt) BALB/c mice, a distinct population of thymocytes expressed huCD2 in 
BALB/c KN2 mice (Figure 3-1 A). Combined with CD1d tetramer staining to 
specifically detect invariant natural killer T (iNKT) cells (Figure 3-2 A), we 
observed that the majority of the IL-4 producing cells were iNKT cells (Figure. 
3-1A). We also used transcription factors staining to distinguish different iNKT 
subsets (Figure 3-2 B), which showed that NKT2 cells were the only cell to 
express huCD2 highly (Figure 3-1 B, C), suggesting they are the major source 
of steady state IL-4 in the thymus, consistent with previous studies (12, 42, 
91). To track the localization of IL-4 producing NKT2 cells, we performed in 
situ CD1d tetramer incubation followed by immunofluorescent staining for 
huCD2 in thymic sections (Figure 3-3 A) (24). The majority of IL-4 producing 
NKT2 cells (huCD2+ CD1d tet+) were found in the UEA-I+ thymic medulla 
(Figure 3-1 D). We employed quantitative histo-cytometry (Figure 3-1 E), 
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which showed more than 80% of IL-4 producing NKT2 cells (huCD2+ CD1d 
tet+) localized in the thymic medulla (Figure 3-1 F, G). These results 
demonstrated that NKT2 cells are the major source of steady state IL-4 in the 
thymus and predominantly localize to the thymic medulla. 
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Figure 3-1. NKT2 cells produce IL-4 in the thymic medulla at steady state. 
(A) Staining of PBS57-CD1d tetramer and human CD2 (huCD2) in ex vivo total thymocytes 
from BALBc wild-type (Wt) and KN2 mice. Gated on live singlets. Data are representative of 4 
experiments. (B) Expression of huCD2 in NKT2, NKT17, NKT1 cells from BALBc KN2 or total 
iNKT cell from BALBc Wt mice. Data are representative of 2 experiments. (C) Percentage of 
iNKT cells in huCD2+ thymocytes from BALBc KN2 mice. Data are pooled from 4 
experiments. (D) Immunofluorescent microcopy of thymic section of BALBc KN2 mice 
(middle), stained with DAPI, PBS57-CD1d tetramer (CD1dt), huCD2 and UEA-I to identify IL-4 
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producing iNKT cells (huCD2+ CD1dt+) in situ, the white dash lines outlines the medullary 
region. The yellow square (middle) outlines the magnified region shown in right, single 
channel of each fluorochrome or merged image. The staining of UEA-I (upper left) was used 
to distinguish Cortex (UEA-I-) and Medulla (UEA-I+), outlined by the white dash line. Data are 
representative of 3 experiments. (E) Each thymic lobe from BALBc Cd1d-/-, Wt or KN2 mouse 
was subjected to histocytometric analysis after immunofluorescent microscopy or to flow 
cytometry analysis. Data are representative of 3 experiments. (F) Localization of IL-4 
producing iNKT cells (huCD2+ CD1dt+) analyzed using histocytometric algorithm. Data are 
representative of 3 experiments. (G) Percentage of huCD2+ iNKT cells localized in thymic 
medulla. Data are pooled from 3 experiments. Each dot represents an individual mouse and 
horizontal bars indicate mean values.  
 
 
Figure 3-2. Detection and gating strategy of iNKT subsets. 
(A) Representative flowcytometry plots of PBS57-CD1d tetramer staining in thymocytes from 
BALBc Cd1d-/- and Cd1d+/+ mouse. (B) Flowcytometric gating strategy to identify thymic iNKT 
cells and iNKT subsets (NKT1, green; NKT2, red; NKT17, blue).  
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Figure 3-3. Specific detection of IL-4 producing NKT2 cells in situ. 
(A) Immunofluorescent microscopy of thymic sections of BALBc Cd1d-/-, Wt and KN2 mouse, 
stained with DAPI, PBS57-CD1d tetramer and huCD2.  
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NKT2 cells require TCR signal for their production of IL-4 in the steady 
state 
T cells can be activated via stimulation of cytokine and/or TCR signals to 
produce cytokines (139). A recent report indicated that thymic tuft cell-derived 
IL-25 promotes the differentiation of NKT2 cells (137). To understand whether 
NKT2 cells might also receive TCR signals in the steady state, we crossed 
BALB/c Nur77GFP mice with BALB/c KN2 mice to obtain the BALB/c 
Nur77GFP/KN2 mice. In Nur77GFP mice, the level of GFP reflects TCR signal 
strength in T cells and is independent of cytokine or inflammatory signals (21, 
140). Interestingly, IL-4 producing NKT2 cells had significantly elevated GFP 
expression compared to NKT1 and NKT17 cells, though lower than stage 0 
iNKT cells (Figure 3-4 A, B), suggesting IL-4 producing NKT2 cells indeed 
receive TCR stimulation in the steady state. This is consistent with the high 
level of Egr2 observed in PLZFhigh iNKT cells (141). We next tested whether 
steady state IL-4 production was dependent on TCR stimulation by 
transferring iNKT enriched thymocytes intrathymically into Wt or Cd1d–/– hosts 
(Figure 3-4 C). huCD2+ NKT2 cells were dramatically reduced 9 days after 
intra-thymic transfer into CD1d–/– hosts compared to Wt hosts (Figure 3-4 D, 
E), while NKT1 and NKT17 cell numbers were not affected (Figure 3-5 A). 
Altogether, this strongly suggests NKT2 cells receive and require TCR signals 
for steady state IL-4 production. Considering the majority of IL-4 producing 
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NKT2 cells were localized in the thymic medulla, it implicates medullary 
antigen presenting cells (APCs) in CD1d dependent stimulation of NKT2 cells.  
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Figure 3-4. NKT2 cells require TCR signal for steady state production of IL-4 
(A) Representative flowcytometry histogram showing Nur77GFP expression of different sub-
populations of thymic iNKT cells enriched from BALBc Nur77GFP or BALBc Wt mice. Data are 
representative of 2 experiments. (B) Normalized Nur77GFP gMFI (to DP) of thymic NKT1, 
NKT17 and IL-4+ NKT2 cells from BALBc Nur77GFP mice. Data are pooled from 2 
experiments. Each dot represents an individual mouse and horizontal bars indicate mean 
values. Ordinary one-way ANOVA, ****p<0.0001. (C) Experimental scheme showing iNKT 
enriched thymocytes from CD45.1+ CD45.2+ BALBc KN2 mice were intra-thymically 
transferred into BALBc Wt (CD45.2+ CD45.2+ or CD45.1+ CD45.1+) or BALBc Cd1d KO 
(CD45.2+ CD45.2+), 9 days later transferred donor iNKT cells were identified and phenotyped 
in flowcytometry after magnetic enrichment of total thymic iNKT cells. (D) Expression of IL-4 
(huCD2) and PLZF in transferred donor iNKT cells 9 days after intra-thymic transfer into 
BALBc Wt or BALBc Cd1d KO host mice. Data are representative of 5 experiments. (E) 
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Percentage (left) and cell number (right) of huCD2+ cells in transferred donor iNKT cells 9 
days after intra-thymic transfer. Data are pooled from 5 experiments. Each dot represents an 
individual mouse and horizontal bars indicate mean values. Unpaired t test, ****p<0.0001. 
 
 
Figure 3-5. Intra-thymic transfer in to Cd1d-/- host does NOT affect donor NKT1 & 
NKT17 in short term 
(A) Cell number of transferred donors NKT1 (left) and NKT17 (right) cells 9 days after intra-
thymic transfer into BALBc Wt or BALBc Cd1d KO host mice. Data are pooled from 5 
experiments. Each dot represents an individual mouse and horizontal bars indicate mean 
values. Unpaired t test, nsp=0.3013 (NKT1) or 0.2534 (NKT17). 
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NKT2 cells require Cd1d in hematopoietic APC to produce IL-4 in the 
steady state 
There are multiple lineages of APCs found in the thymic medulla, including 
stromal derived APC (thymic epithelial cells) as well as hematopoietic origin 
APCs (B cells, classical dendritic cells, plasmacytoid dendritic cells and 
macrophages) (142), all of which express CD1d (Figure 3-7 B, 3-10 A, 3-10 C, 
data not shown)(143, 144). Therefore, we decided to first distinguish the role 
of stromal and hematopoietic APCs in supporting NKT2 cells for steady state 
production of IL-4. For this purpose, we created bone marrow chimeras in 
which Cd1d was selectively deficient in either stromal or hematopoietic APCs 
(Figure 3-6 A). The bone marrow chimeras were used as hosts for intra-thymic 
transfer of iNKT enriched thymocytes similar to that described above (Figure 
3-6 A, Figure 3-4 C). Strikingly, steady state IL-4 production in NKT2 cells was 
dramatically decreased upon intra-thymic transfer into chimeras where Cd1d 
was selectively deficient in hematopoietic cells (Cd1d KO BM to Wt), while 
maintained in chimeras where Cd1d was selectively deficient in stromal cells 
(Wt BM to Cd1d KO) (Figure 3-6 B, C). These results suggest only 
hematopoietic APCs stimulate NKT2 cells to produce IL-4 in the steady state.  
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Figure 3-6. Steady state IL-4 production in NKT2 requires Cd1d solely in hematopoietic 
APC 
(A) Four type of BALBc bone marrow chimeras were created, including total Cd1d sufficiency, 
total Cd1d deficiency, Cd1d selectively deficient in Stromal cells and Cd1d selectively 
deficient in hematopoietic cells, to serve as recipient mice for intra-thymic transfer. (B) 
Expression of IL-4 (huCD2) and PD-1 in transferred donor iNKT cells 9 days after intra-thymic 
transfer into BLABc bone marrow chimeras with total Cd1d sufficiency (Wt BM to Wt, far left), 
total Cd1d deficiency (Cd1d KO BM to Cd1d KO, middle left), Cd1d selectively deficient in 
Stromal cells (Wt BM to Cd1d KO, middle right) and Cd1d selectively deficient in 
hematopoietic cells (Cd1d KO BM to Wt, far right), respectively. Data are representative of 3 
experiments. (C) Percentage (left) and cell number (right) of huCD2+ cells in transferred donor 
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iNKT cells 9 days after intra-thymic transfer. Ordinary one-way ANOVA; nsp=0.9967 (left, A-C) 
or 0.7751 (left, B-D) or 0.8656 (right, A-C) or >0.9999 (right, B-D), **p=0.0024 (right, B-C) or 
0.0010 (right, C-D), ***p=0.0001 (left) or 0.0009 (right, A-B) or 0.0004 (right, A-D), 
****p<0.0001. (D) Expression of IL-4 (huCD2) and PD-1 in thymic iNKT cells from F1 
littermate control (left) or F1 FoxN1Cre+ Cd1dfl/fl (right) mice. Data are representative of 5 
experiments. (E) Percentage (left) and cell number (right) of huCD2+ cells in thymic iNKT cells 
from F1 littermate control or F1 FoxN1Cre+ Cd1dfl/fl mice. Data are pooled from 5 
experiments. Each dot represents an individual mouse and horizontal bars indicate mean 
values. Unpaired t test, nsp=0.2994 (left) or 0.9180 (right). 
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To confirm this result, we sought to target Cd1d deficiency specifically in 
thymic epithelial cells (TECs) using FoxN1Cre. However, NKT2 and NKT17 
cells are scarce in B6 mice (12), thus it was desirable to do this and further 
tissue specific gene deletion experiments in BALB/c mice. However, Cd1dfl/fl 
mice and Cre-recombinase transgenic mice are most readily available on the 
B6 background. Interestingly, the thymic iNKT cells in B6 × BALB/c F1 mice 
resemble that of in BALB/c mice (Figure 3-8 A-C). Thus, we developed a 
strategy to achieve conditional CD1d deficiency in B6 × BALB/c F1 mice. 
Briefly, we backcrossed B6 Cd1dfl/fl to BALB/c KN2 for at least 10 generations 
to obtain BALB/c Cd1dfl/fl-KN2. B6 Cre-recombinase transgenic mice were first 
crossed to B6 Cd1dfl/fl mice to obtain B6 Cre-Cd1dfl/fl mice. Then the B6 Cre-
Cd1dfl/fl mice were further crossed with BALB/c Cd1dfl/fl-KN2 mice to generate 
F1 Cre-Cd1dfl/fl (Figure 3-7 A). Using this experimental strategy, we generated 
F1 FoxN1Cre-Cd1dfl/fl-KN2 to efficiently target Cd1d deficiency in TECs 
(Figure 3-7 B, C). huCD2 expression was comparable in iNKT cells between 
F1 FoxN1Cre-Cd1dfl/fl-KN2 and littermate controls (Figure 3-6 D, E). This is 
consistent with the results we showed above in intra-thymic transfer of BM 
chimeras (Figure 3-6 A-C), suggesting that CD1d in TECs is dispensable for 
stimulating NKT2 cells to produce IL-4 in the steady state.  
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Figure 3-7. Experimental strategy of generating F1 Cre-CD1dfl/fl-KN2 mouse & 
targeting of Cd1d with FoxN1Cre 
(A) Experimental scheme showing generation of F1 Cre-Cd1dfl/fl-KN2 or Littermate control 
mice through cross breeding of B6 Cre-Cd1dfl/fl with BALBc Cd1dfl/fl-KN2 mice. (B) 
Representative flowcytometry histogram showing expression of CD1d in thymic epithelial cells 
(TECs, EpCAM+ CD45-) from F1 littermate control, F1 FoxN1Cre Cd1dfl/fl and BALBc Cd1d 
KO mice. (C) Frequency of CD1d+ cells of TECs from F1 littermate control or F1 FoxN1Cre+ 
Cd1dfl/fl mice. 
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Figure 3-8. B6 Cd1dfl/fl mouse backcrossed to BALBc KN2 mouse. 
(A) Expression of huCD2 and PLZF (upper row), T-bet and ROR-γt (middle row) in thymic 
iNKT cells, and expression of T-bet and PLZF in ROR-γt- (lower row) thymic iNKT cells from 
B6 Wt, B6 KN2, BALBc KN2 and BALBc Cd1dfl/fl-KN2 mice. (B) Frequency of huCD2+ cells 
(far left panel 1, red) and cell number of huCD2+ cells (panel 2, red), NKT1 cells (panel 3, 
green), PLZFhigh cells (panel 4, pink) and NKT17 cells (panel 5, blue) in thymic iNKT cells 
from B6 KN2, BLABc KN2 or BALBc Cd1dfl/fl-KN2 mice. (C) Cell number of double positive 
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(DP) (far left), CD4 single positive (SP) (middle) and CD8 single positive (SP) (far right) 
thymocytes from B6 KN2, BLABc KN2 or BALBc Cd1dfl/fl-KN2 mice. 
 
  
109 
 
CD11c+ APCs support steady state IL-4 production in NKT2 cells in CD1d 
dependent manner 
To define the hematopoietic APC in the thymus that is required to stimulate 
NKT2 cells to produce IL-4 in the steady state, we expanded our F1 Cre-
Cd1dfl/fl strategy (Figure 3-7 A). CD1d expression was specifically abrogated 
in different antigen presenting cells using animals expressing Cre under 
various tissue specific promoters. Effective depletion of CD1d was observed 
in thymic B cells in F1 MB1Cre-Cd1dfl/fl mice (Suppl. 6A-B). However, the 
frequency and cell number of huCD2+ iNKT cells was not affected by CD1d 
deficiency in B cells (Figure 3-9 A, B). However, in F1 CD11cCre-Cd1dfl/fl 
mice, we observed a substantial decrease of huCD2 expression in iNKT cells 
(Figure 3-9 C, D), indicating an essential role for CD11c+ APCs in induction of 
steady state IL-4.  
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Figure 3-9. Steady state IL-4 production relies on CD1d in CD11c expressing APCs. 
(A) Expression of IL-4 (huCD2) and PD-1 in thymic iNKT cells from F1 littermate control (left) 
or F1 MB1Cre+ Cd1dfl/fl (right) mice. Data are representative of 5 experiments. (B) Percentage 
(left) and cell number (right) of huCD2+ cells in thymic iNKT cells from F1 littermate control or 
F1 MB1Cre+ Cd1dfl/fl mice. Data are pooled from 5 experiments. Each dot represents an 
individual mouse and horizontal bars indicate mean values. Unpaired t test, nsp=0.9852 (left) 
or 0.1456 (right). (C) Expression of IL-4 (huCD2) and PD-1 in thymic iNKT cells from F1 
littermate control (left) or F1 CD11cCre+ Cd1dfl/fl (right) mice. Data are representative of 7 
experiments. (D) Percentage (left) and cell number (right) of huCD2+ cells in thymic iNKT cells 
from F1 littermate control or F1 CD11cCre+ Cd1dfl/fl mice. Data are pooled from 7 
experiments. Each dot represents an individual mouse and horizontal bars indicate mean 
values. Unpaired t test, ****p<0.0001. 
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Although CD11c is an important marker for dendritic cells, it was previously 
shown, and we confirmed here, that CD11cCre targets multiple lineages of 
myeloid cells, including classical dendritic cells (cDC), plasmacytoid dendritic 
cells (pDC) and macrophages (suppl. 6C-D) (145-147). So, although this 
result strongly suggests that CD11c+ APCs are essential for the steady state 
NKT2 IL-4 production, either cDC, pDC or macrophages (F4/80+ Mertk+ cells) 
might be involved. 
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Figure 3-10. Targeting of Cd1d with MB1Cre & CD11cCre, respectively. 
(A) Representative flowcytometry histogram showing expression of CD1d in thymic B cells 
from F1 littermate control, F1 MB1Cre Cd1dfl/fl and BALBc Cd1d KO mice. (B) Frequency of 
CD1d+ cells of thymic B cells from F1 littermate control or F1 MB1Cre+ Cd1dfl/fl mice. (C) 
Representative flowcytometry histogram showing expression of CD1d in thymic macrophages 
(F4/80+ Mertk+, far left), cDC (middle) and pDC (far right) from F1 littermate control, F1 
CD11cCre Cd1dfl/fl and BALBc Cd1d KO mice. (D) Frequency of CD1d+ cells of thymic 
macrophages (F4/80+ Mertk+, far left), cDC (middle) and pDC (far right) from F1 littermate 
control or F1 MB1Cre+ Cd1dfl/fl mice. 
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F4/80+ Mertk+ Macrophages are essential for steady state IL-4 production 
in NKT2 cells 
We sought to further distinguish the role of cDC, pDC and macrophages in the 
CD1d mediated induction of IL-4 by NKT2 cells. For this purpose, we 
generated F1 Zbtb46Cre-CD1dfl/fl mice and observed a specific loss of CD1d 
in cDC (Figure 3-11 A, B) (145). Nonetheless, the frequency and number of 
huCD2+ iNKT cells in the thymus was not affected upon the depletion of Cd1d 
in cDC (Figure 3-12 A, B), suggesting the CD1d mediated interaction between 
cDC and iNKT cells is not required for NKT2 steady state IL-4 production. To 
evaluate the impact of pDC on steady state IL-4, pDC were effectively 
depleted using the F1 BDCA2-DTR mice with repeated injection of diphtheria 
toxin (DT) every other day (Figure 3-13 A-C). After 9 days of DT 
administration, we observed a mild decrease of huCD2+ iNKT cells in the 
pDC-depleted F1 BDCA2-DTR mice compared to F1 littermate control mice. 
This indicates pDC may play a supportive role in steady state IL-4 production.  
 
Finally, we examined the role of macrophages by generating LysMCre-
Csf1rLsL-DTR mice (148) on an F1 background. F4/80+ Mertk+ macrophages 
were effectively ablated with a 9-day course of DT administration every other 
day in these mice (Figure 3-13 D, E). Moreover, flow cytometric analysis of 
various myeloid cells and lymphocytes in the thymus (Figure 3-14 A) showed 
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cells of other lineages were not affected (Figure 3-13 E). Strikingly, depletion 
of the relatively small population of F4/80+ Mertk+ macrophages in the thymus 
led to a substantial decrease of IL-4 production by NKT2 cells (Figure 3-12 E). 
NKT2 derived IL-4 was previously shown to condition CD8+ T cells to become 
memory phenotype, characterized by the expression of the transcription factor 
Eomes (12, 41). Consistent with a loss of NKT2 derived IL-4, we observed a 
marked decrease in Eomes+ CD8+ T cells after depletion of macrophages 
(Figure 3-12 G, H). Together, these results show that thymic macrophages 
(F4/80+ Mertk+ cells) are critical for stimulating thymic NKT2 cells to produce 
IL-4 in the steady state.  
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Figure 3-11. Targeting of Cd1d with Zbtb46Cre. 
(A) Representative flowcytometry histogram showing expression of CD1d in thymic cDC from 
F1 littermate control, F1 Zbtb46Cre+ Cd1dfl/fl and BALBc Cd1d KO mice. (B) Frequency of 
CD1d+ cells of thymic cDC from F1 littermate control or F1 Zbtb46Cre+ Cd1dfl/fl mice. 
 
 
Figure 3-12. Macrophages/phagocytes are essential for steady state IL-4 production in 
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NKT2 cells. 
(A) Expression of IL-4 (huCD2) and PD-1 in thymic iNKT cells from F1 littermate control (left) 
or F1 Zbtb46Cre+ Cd1dfl/fl (right) mice. Data are representative of 7 experiments. (B) 
Percentage (left) and cell number (right) of huCD2+ cells in thymic iNKT cells from F1 
littermate control or F1 Zbtb46Cre+ Cd1dfl/fl mice. Data are pooled from 7 experiments. Each 
dot represents an individual mouse and horizontal bars indicate mean values. Unpaired t test, 
nsp=0.7468 (left) or 0.5010 (right). (C) Expression of IL-4 (huCD2) and PD-1 in thymic iNKT 
cells from F1 littermate control (left) or F1 BDCA2-DTR+/- (right) mice after a 9-day course of 
DT treatment. Data are representative of 3 experiments. (D) Percentage (left) and cell number 
(right) of huCD2+ cells in thymic iNKT cells from F1 littermate control or F1 BDCA2-DTR+/- 
mice after a 9-day course of DT treatment. Data are pooled from 3 experiments. Each dot 
represents an individual mouse and horizontal bars indicate mean values. Unpaired t test, 
*p=0.0249 (left) or 0.011 (right). (E) Expression of IL-4 (huCD2) and PD-1 in thymic iNKT cells 
from F1 littermate control (left) or F1 LysMCre+ Csf1rLsL-DTR+/- (right) mice after a 9-day course 
of DT treatment. Data are representative of 7 experiments. (F) Percentage (left) and cell 
number (right) of huCD2+ cells in thymic iNKT cells from F1 littermate control or F1 LysMCre+ 
Csf1rLsL-DTR+/- mice after a 9-day course of DT treatment. Data are pooled from 7 experiments. 
Each dot represents an individual mouse and horizontal bars indicate mean values. Unpaired 
t test, ****p<0.0001. (G) Expression of Eomes in thymic CD8 SP from F1 littermate control 
(left) or F1 LysMCre+ Csf1rLsL-DTR+/- (right) mice after a 9-day course of DT treatment. Data are 
representative of 6 experiments. (H) Percentage (left) and cell number (right) of Eomes+ cells 
in thymic CD8 SP from F1 littermate control or F1 LysMCre+ Csf1rLsL-DTR+/- mice after a 9-day 
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course of DT treatment. Data are pooled from 6 experiments. Each dot represents an 
individual mouse and horizontal bars indicate mean values. Unpaired t test, ***p=0.0002 (left), 
****p<0.0001 (right). 
 
 
Figure 3-13. Depletion of pDC and macrophages/phagocytes in respective transgenic 
mouse models. 
(A) Experimental scheme showing the F1 littermate control and F1 BDCA2-DTR KN2 mice 
were injected intraperitoneally (i.p.) with DT every other day for 5 times in a 9-day course, and 
the thymic iNKT cells and pDC were analyzed at day 9. (B) Expression of CD11c and PDCA-
1 in thymic cells and gating of pDC (CD11cintermediate PDCA-1+) from F1 littermate control and 
F1 BDCA2-DTR+/- KN2 mice after a 9-day course of DT treatment. (C) Cell number of thymic 
pDC in F1 littermate control and F1 BDCA2-DTR+/- KN2 mice after a 9-day course of DT 
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treatment. (D) Experimental scheme showing the F1 littermate control and F1 BDCA2-DTR 
KN2 mice were injected intraperitoneally (i.p.) with DT every other day for 5 times in a 9-day 
course, and the thymic iNKT cells and myeloid cells were analyzed at day 9. (E) Expression 
of Mertk and F4/80 in thymic cells and gating of macrophages/phagocytes (F4/80+ Mertk+) 
from F1 littermate control and F1 LysMCre+ Csf1rLsL-DTR+/- KN2 mice after a 9-day course of 
DT treatment. (F) Cell number of thymic F4/80+ Mertk+ macrophages/phagocytes, B cells, 
cDC, pDC, eosinophils and neutrophils in F1 littermate control and F1 LysMCre+ Csf1rLsL-DTR+/- 
KN2 mice after a 9-day course of DT treatment. 
 
 
Figure 3-14. Gating strategy of myeloid cell populations in the thymus. 
(A) Flowcytometric gating strategy to identify thymic B cells (CD19+ B220+), neutrophils 
(Ly6G+ SiglecF-), eosinophils (Ly6G-, SiglecF+), cDC (CD11chigh, MHC-IIhigh), pDC 
(CD11cintermediate, B220+, MHC-IIlow) and macrophages/phagocytes (F4/80+ Mertk+). 
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Discussion 
This and previous studies collectively showed that NKT2 cells are the major 
source of IL-4 in the thymus in the steady state (12, 41, 91). This type II 
cytokine-enriched thymic environment strongly influences thymocyte 
development through the induction of large numbers of innate CD8 T cells 
(12, 41), although the biological rationale for this is not yet clear. It may 
enhance neonatal immunity, as thymic IL-4 is more abundant early in life (12). 
Alternatively, thymic IL-4 may enhance tolerance of conventional T cells to 
self-antigens that are uniquely produced during type II immune responses, 
especially those derived from IL-4 induced genes.  
 
In this study we further demonstrated that IL-4 producing NKT2 cells reside in 
the thymic medulla and require continuous TCR signal for their steady state 
production of IL-4, suggesting a cognate interaction between NKT2 cells and 
thymic antigen presenting cells (APC) in the medulla in the steady state. Both 
the selective activation of a subset of iNKT cells and the medullary location 
are surprising findings that raise additional questions. 
 
The medulla is an important site of iNKT cell differentiation 
iNKT cells are initially selected at the most immature “stage 0” state, through 
the interactions among DP thymocytes in the thymic cortex (5, 7, 8). 
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Nonetheless, the thymic medulla is crucial for the continued development of 
iNKT cells, as mature thymic iNKT cells (CD44+) were greatly reduced in 
Relb−/− thymic epithelial cell (TEC) kidney capsule grafts, which specifically 
lack medullary thymic epithelial cells (mTEC) (25). In line with this, we 
recently showed that CCR7+ iNKT cells represent a multipotent precursor for 
all three iNKT effector subsets (NKT1, NKT2 and NKT17) and CCR7 
facilitates migration of this precursor from the cortex to the medulla (132). 
Collectively, these findings put forward the notion that initial selection happens 
in cortex while further differentiation into thymic effector subsets is reinforced 
in the medulla. Indeed, IL-15 produced by medullary thymic epithelial cells 
was essential for the generation of T-bet+ NKT1 cells (25, 124) and medullary 
thymic tuft cells were shown to influence the differentiation of thymic NKT2 
cells, possibly through production of IL-25 (137).   
 
Medullary macrophages activate iNKT cells 
In addition to providing cytokines that impact the differentiation or retention of 
iNKT cells, we here showed that NKT2 cells in particular were activated by 
CD1d expressing APC in the medulla. This is consistent with an earlier study 
that showed that CD1d was required for maturation of thymic iNKT cells 
beyond the positive selection of “stage 0 iNKT cells” (87), albeit not for their 
retention. We further demonstrated that thymic macrophages were the 
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predominant APC required for NKT2 cells to produce IL-4 through a CD1d 
mediated interaction. Thymic macrophages are distributed throughout the 
cortex and medulla (149, 150) (data not shown), and are believed to serve as 
scavengers that play an essential role in clearing apoptotic thymocytes. 
However, previous reports also showed thymic macrophages express both 
MHC-I and MHC-II and may possess antigen presenting activity (149-152) 
(data not shown). Interestingly, macrophages are enriched in genes involved 
in lipid metabolism (153). Moreover, recent studies showed that macrophages 
were required to stimulate iNKT cells to produce IL-4 in context of sterile liver 
injury (106) and influenza infection (154). Those CD1d dependent interactions 
facilitated recovery from injury and optimal B cell immunity, respectively. 
Collectively, these data indicate that macrophages can serve as important 
APC to present lipid antigens to iNKT cells under certain circumstances. 
However, the nature of these lipid antigens, and whether they are distinct from 
the lipid antigens that mediate positive selection of iNKT cells in the thymic 
cortex, remains to be elucidated,    
 
NKT2 cells are selectively activated in the thymus 
Not only do NKT2 cells produce the highest levels of IL-4 amongst thymic 
iNKT, they also expressed the highest level of Nur77GFP, indicating they are 
perceiving stronger TCR signaling. This is consistent with the elevated Egr2 
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level in PLZFhigh iNKT cells (141). This TCR signal is essential for IL-4 
production, as it ceased after adoptive transfer in Cd1d KO hosts. High TCR 
signal strength also favors the differentiation of thymic NKT2 cells (PLZFhigh 
iNKT), as such cells were substantially decreased in mice with weakened 
TCR signaling (SKG, YYAA mice) (141, 155). How do NKT2 cells perceive 
CD1d/self-lipid ligands differently than NKT1 and NKT17 when they all utilize 
a “semi-invariant” TCR? One possibility is that Vβ usage alters the fine 
specificity of the iNKT cells. Indeed, the three iNKT subsets have distinct and 
stable Vβ repertoires (12, 88, 141) with NKT2 cells (PLZFhigh iNKT) showing 
higher TCR density and a preferential usage of Vβ7 (12, 141). In a model 
system where retrogenic mice expressed various iNKT TCR β chains, it was 
demonstrated that the frequency of different iNKT subsets was governed by 
the half-life of TCR-Ag-CD1d interaction (90). Similarly, another study using 
somatic nuclear transfer to generate mouse strains bearing different 
monoclonal iNKT TCRs showed higher TCR avidity correlates with higher 
frequency of PLZFhigh iNKT cells (88). Earlier study suggests Vβ7+ iNKT cells 
might have a higher avidity for CD1d/self-lipid ligands than iNKT cells bearing 
other Vβs (89). Thus, it is possible that biased TCR Vβ gene usage led to 
differential TCR signaling events that further impacted the differentiation of 
iNKT subsets. Another possibility is that TCR level dictate the perceived 
stimulus. NKT2 cells express the highest level of surface TCR, followed by 
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NKT17, and NKT1 have quite low levels. Indeed, TCR density was directly 
shown to influence the differentiation of iNKT subsets (156). It was recently 
suggested that SLAM family receptors (SFR) facilitate NKT development by 
reducing TCR strength after position selection, and SFR deficiency skewed 
the subset distribution, most strongly affecting NKT1 cells (157). 
 
In conclusion, we showed IL-4 producing NKT2 cells reside in thymic medulla 
are the major source of steady state IL-4 in the thymus. The steady state 
production of IL-4 in NKT2 cells depends on continuous TCR signal mediated 
by hematopoietic APC, predominantly by thymic macrophages. Moreover, 
considering previous reports discussed above, all these data suggest a model 
for the differentiation steps of thymic iNKT cells that, 1) the initial positive 
selection among DP thymocytes generates the most immature “stage 0 iNKT 
cells” in the thymic cortex; 2) with the upregulation of PLZF and CCR7, the 
iNKT multi-potent precursors migrate from cortex to medulla; 3) The 
differentiation into effector subsets (NKT1, NKT2 and NKT17) from PLZF+ 
CCR7+ iNKT precursors is influenced by various factors in thymic medulla. 
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Material and Methods 
 
Table 3-1 Key resources table 
Mice 
Reagent type (species) or
resource
Designation Source or reference Identifiers
Additional
informati
on
antibody anti-CD4 BD Biosciences Cat # 563331 (1:400)
antibody anti-CD8α BD Biosciences Cat # 563786 (1:400)
antibody anti-CD24 BioLegend Cat # 101824 (1:200)
antibody anti-CD44 TONBO Biosciences Cat # 80-0441-U025 (1:200)
antibody anti-human CD2 BioLegend Cat # 309218 5μL/test
antibody anti-TCRβ BD Biosciences Cat # 563221 (1:200)
antibody anti‑PD-1 BioLegend Cat # 135213 (1:100)
antibody anti-CD45.1 BioLegend Cat # 110738 (1:200)
antibody anti-CD45.2 eBioscience Cat # 11-0454-81 (1:200)
antibody anti-CD45 eBioscience Cat # 25-0451-82 (1:200)
antibody anti-B220 BioLegend Cat # 103244 (1:200)
antibody anti-CD11c eBioscience Cat # 47-0114-82 (1:200)
antibody anti-CD11b eBioscience Cat # 47-0112-82 (1:200)
antibody anti‑F4/80 eBioscience Cat # 47-4801-82 (1:200)
antibody anti-CD122 BD Biosciences Cat # 562960 (1:100)
antibody anti-PLZF BD Biosciences Cat # 563490 (1:200)
antibody anti-ROR-γt BD Biosciences Cat # 562684 (1:200)
antibody anti-T-bet BioLegend Cat # 644824 (1:200)
antibody anti-Mertk BioLegend Cat # 151504 (1:200)
antibody anti-CD1d
eBioscience & BD
Biosciences
Cat # 12-0011-81 & 553846 (1:200)
antibody anti-CD19 TONBO Biosciences Cat # 60-0193-U100 (1:200)
antibody anti-PDCA-1 BioLegend Cat # 127106 (1:200)
antibody anti-Thy1.2 eBiosiences Cat # 47-0902-82 (1:400)
antibody anti-SiglecF BD Biosciences Cat # 740280 (1:200)
antibody anti-Ly6G BioLegend Cat # 127610 (1:200)
antibody anti-MHC-II BioLegend Cat # 107653 (1:1000)
antibody anti-EpCAM BioLegend Cat # 118214 (1:200)
antibody Goat-anti-R Phycoerythrin (PE) Abcam Cat # ab34721 (1:200)
antibody w hole rabbit sera anti-R Phycoerythin (PE) Novus Biologicals Cat # NB120-7011 (1:200)
antibody
Donkey-anti-Rabbit AF555 &
Goat-anti-Rabbit AF555
Invitrogen
Cat # A31572 &
A21429
(1:400)
antibody Donkey-anti-Goat AF555 Invitrogen Cat # A21432 (1:400)
Other Ulex Europaeus Agglutinin I (UEA I) VECTOR LOBORATORY FL-1061 (1:200)
Other Strepavidin PE Invitrogen Cat # S21388
commercial assay or kit Viability dye Ghost Dye™ Red 780 TONBO Biosciences Cat # 13-0865-T100 (1:500)
commercial assay or kit Magnetic columns Miltenyi Cat # 130-042-401
commercial assay or kit anti-PE microbeads Miltenyi Cat # 130-048-801
commercial assay or kit tyramide amplif ication kit PerkinElmer Cat # NEL745001KT
chemical compound, drug Collagenase D Roche Cat # 11088882001 1mg/mL
chemical compound, drug Mouse serum Jackson ImmunoResearch Cat # 015-000-120 5μL/test
chemical compound, drug DNase I Roche Cat # 10104159001 100 U/ml
chemical compound, drug Liberase TH Roche Cat # 5401127001
0.05%
[w /v]
chemical compound, drug Diptherial toxin Sigma-Aldrich Cat # D0564
Diluted in
PBS
softw are, algorithm Prism 7 GraphPad https://w w w .graphpad.com/
softw are, algorithm ImageJ ImageJ https://imagej.nih.gov/ij/
softw are, algorithm Flow Jo v10 TreeStar - Flow jo
https://w w w .flow jo.com/solutions/f l
ow jo
 Key Resources Table
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B6 (C57BL/6NCr) mice were purchased from the National Cancer Institute. 
BALB/cBYJ, CD45.1+ BALB/cBYJ (CByJ.SJL(B6)-Ptprca/J), Cd1d-/- BALB/c. 
(C.129S2-Cd1tm1Gru/J), Cd1dfl/fl B6, FoxN1Cre B6, MB1Cre B6, CD11cCre 
B6, Zbtb46Cre B6, BDCA2-DTR B6 mice were obtained from the Jackson 
Laboratory. KN2 BALB/cBYJ, Nur77GFP BALBc and KN2 B6 mice have been 
previously described (12). LysMCre-Csf1rLsL-DTR B6 mice were kindly provided 
by Dr. Marc Jenkins at University of Minnesota. CD45.1+ CD45.2+ KN2 
BALB/cBYJ, Nur77GFP KN2 BALBc, FoxN1Cre Cd1dfl/fl KN2 F1, MB1Cre 
Cd1dfl/fl KN2 F1, CD11cCre Cd1dfl/fl KN2 F1, Zbtb46Cre Cd1dfl/fl KN2 F1, 
BDCA2-DTR KN2 F1, LysMCre Csfr1LsL-DTR KN2 F1, LysMCre Csfr1LsL-DTR F1 
mice as well as littermate control mice for each strain were generated through 
crossbreeding at University of Minnesota. Cd1dfl/fl KN2 BALB/c mice were 
generated through using Cd1dfl/fl B6 mice backcrossed to KN2 BALB/c mice 
for at least 10 generations at University of Minnesota. All animal work was 
conducted in compliance with the protocols approved by the Institutional 
Animal Care and Use Committee of the University of Minnesota. 
 
Diphtherial toxin treatment 
BDCA2-DTR F1 and littermate control mice were injected intraperitoneally 
(i.p.) with diphtherial toxin (DT) every other day for 9 days (5 injections in total, 
500ng of DT in 100μL PBS for the 1st injection on 1st day, 100ng of DT in 
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100μL PBS for all subsequent injections). LysMCre Csfr1LsL-DTR F1 and 
littermate control mice were injected i.p. with diphtherial toxin (DT) every other 
day for 9 days (5 injections in total, 100ng of DT in 100μL PBS for the all 5 
injections). Mice were used the day after the last injections. 
 
Intra-thymic transfer 
iNKT enriched thymocytes were prepared through depletion of CD8+ and 
CD24+ cells (via immunomagnetic selection [Miltenyi]) in thymocytes from 
CD45.1+ CD45.2+ KN2 BALB/cBYJ mice. Intra-thymic transfers were 
performed on congenic host mice through ultrasound imaging guidance. 
Ultrasound imaging guided intra-thymic transfer is described in detail 
previously (128). 
 
Bone marrow chimera 
Bone marrow cells were directly flushed out from the femurs and tibias of 
donor mice (BALB/c Wt or BALB/c Cd1d-/-) and depleted of T cells via 
immunomagnetic depletion (Miltenyi) of CD8+ and CD3+ cells. Recipient mice 
(BALB/c Wt or BALB/c Cd1d-/-) received a total lethal dose of 600 rads. 
Irradiations were done in 2 doses (300 rads each) separated by a period of 3-
4 hours. 2 hours after last irradiation, recipient mouse received at least 4×106 
of T-cell-depleted bone marrow donor cells through intravenous injection via 
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tail vein. Bone marrow chimeras were used at 8 weeks after introduction of 
bone marrow donor cells. 
 
Enrichment of iNKT cells 
Thymocytes were prepared in single cell suspension and incubated with PE-
CD1d-PBS57 tetramer at 4℃ for 30 min followed by immunomagnetic 
enrichment using anti-PE microbeads per manufacturer’s instructions 
(Miltenyi). 
 
Preparation of lymphocytes and flow cytometric analysis 
Thymocytes were prepared in single cell suspension through mashing thymi 
and filtering through 70 μM cell strainers (FALCON), or digestion with 
collagenase D (concentration?) at 37℃ for 30 min before mashing and 
filtration through 70 μM cell strainers. The thymic epithelial cells were 
prepared as previously described (Ref). Cells were incubated with Fc block 
(Tonbo) and mouse serum (Jackson ImmunoResearch) for 15 min at 4℃ 
before staining with antibodies to surface markers and viability dye (Tonbo) for 
45 min at 4℃. For intracellular staining of transcription factors, cells were 
fixed and permealized with a Foxp3 staining buffer set (eBioscience) after 
staining with antibodies to surface markers, then were incubated with 
antibodies to transcription factors in permealization buffer for 45 min at 4℃. 
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Biotinylated PBS57 loaded or unloaded CD1d monomers were from the 
tetramer core of the US National Institutes of Health and tetramerized with 
streptavidin-PE at the ratio of 4:1. All antibodies were purchased from 
eBioscience, BD Biosciences or BioLegend, unless otherwise indicated. See 
table 3-1 for a list of antibodies and other reagents used in this study. 
Samples were acquired on a BD LSR Fortessa or BD Fortessa X-20 and data 
were analyzed with FlowJo 10 (Treestar). Samples were SSC-A/FSC-A gated 
to exclude debris, SSC-A/SSC-W gated to select single cells, then gated to 
exclude viability dye+ dead cells. 
 
Immunofluorescence and histocytometric analysis 
For CD1d tetramer based immunofluorescence, the fresh thymic lobe was 
incubated PE-CD1d-PBS57 tetramer (50 μL of 1×PBS containing 2% FBS + 2 
μL of CD1d tetramer in 96 well plate) at 4℃ overnight, then washed with PBS 
for 3 times, then fixed in 4% paraformaldehyde (PFA) at 4℃ for 1 hour 
followed by incubation in 30% (w/v) sucrose for overnight. Tissues were 
further snap frozen in Optimal Cutting Temperature Compound (Tissue-Tek) 
and stored at -80℃ before sectioning (5-7 μm) on a Cryostat (Leica). The 
immunofluorescence was performed in CAS block solution (Invitrogen) as 
follows: 1 hour blocking in CAS block solution at room temperature (RT), 2 
hours incubation at RT with primary antibodies mixture including anti-PE 
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antibody (Goat polyclonal to R Phycoerythrin, Abcam; or rabbit whole 
antisera, Novus Biologicals) and other antibodies, wash 3 times, 1 hour 
incubation at RT with secondary antibodies mixture (Donkey anti Goat AF555, 
Invitrogen; or Goat-anti-Rabbit-AF555, Invitrogen), wash 3 times, mount 
overnight in mounting media containing DAPI (ProLong® Diamond Antifade 
Mountant with DAPI).  
For human CD2 (huCD2) immunofluorescence, the tissue was stained with 
anti-huCD2 (RPA2) antibody followed by tyramide-based amplification per 
manufacturer’s instructions (PerkinElmer). The images were collected on a 
Leica DM6000B Epi-Fluorescent microscope. The histocytometric analysis to 
quantify localization was performed in ImageJ, Flowjo and Prism as previously 
described (24, 130). 
 
Statistical analysis 
Unpaired two-tailed t-tests, and one-way ANOVA were used for data analysis 
and calculation of p values in Prism software (GraphPad). 
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Chapter 4 
ARTC2.2/P2RX7 Signaling during Cell Isolation Distorts Function and 
Quantification of iNKT subsets. 
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Overview 
Peripheral invariant natural killer T (iNKT) cells express high levels of the 
extracellular ATP receptor P2RX7 in mice. High extracellular ATP 
concentrations or NAD-mediated P2RX7 ribosylation by the enzyme ARTC2.2 
can induce P2RX7 pore formation and cell death. Because both ATP and NAD 
are released during tissue preparation for analysis, cell death through these 
pathways may compromise the analysis of iNKT. Indeed, ARTC2.2 blockade 
enhanced recovery of viable liver iNKT. The expression of ARTC2.2 and 
P2RX7 on distinct iNKT subsets is unclear, however, as is the impact of 
recovery from other nonlymphoid sites. In this study, we performed a 
comprehensive analysis of ARTC2.2 and P2RX7 expression in iNKT cells in 
diverse tissues, at steady-state. NKT1 cells express high levels of both 
ARTC2.2 and P2RX7 compared with NKT2, NKT17, and CD8+ circulating 
memory subsets. Using nanobody-mediated ARTC2.2 antagonism, we 
showed that ARTC2.2 blockade enhanced NKT1 recovery from nonlymphoid 
tissues during cell preparation. Moreover, blockade of this pathway was 
essential to preserve functionality, viability, and proliferation of iNKT cells. In 
summary, our data show that short-term in vivo blockade of the 
ARTC2.2/P2RX7 axis permits much improved flow cytometry–based 
phenotyping and enumeration of murine iNKT from nonlymphoid tissues, and 
it represents a crucial step for functional studies of this population. 
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Introduction 
During preparation of ex vivo cell suspensions or in response to microbial 
infections, inflammation, or tumor growth, high concentrations of the 
nucleotides ATP and NAD can be released from apoptotic, necroptotic, or 
stressed cells (158). Extracellular ATP (eATP) stimulates P2RX7, which is a 
nonselective ligand-gated ion channel expressed by several immune cell 
types. Prior research focused on myeloid cells (159, 160), but P2RX7 is also 
expressed by lymphocyte populations (161-164). When activated by high 
concentrations of eATP, P2RX7 forms reversible nonselective pores that can 
mediate activation signals but can ultimately lead to cell death if eATP 
exposure persists (159, 165). ADP-ribosylation of P2RX7 by the ectoenzyme 
ARTC2.2, in contrast, induces irreversible pore formation and subsequent cell 
death. ARTC2.2 is activated by extracellular NAD (166). Importantly, ARTC2.2 
activation-induced P2RX7 pore formation occurs at much lower 
concentrations of NAD compared with that of eATP (167). ARTC2.2 is 
catalytically active even when cells are at 4°C (158). The subsequent 
formation of P2RX7 pores, however, only happens at temperatures above 
24°C, suggesting the effects of ARTC2.2-mediated ribosylation could be 
manifested during tissue processing that involves incubation at room 
temperature or 37°C—such as the steps necessary for lymphocyte isolation 
from nonlymphoid tissues (168, 169). Indeed, previous studies have shown 
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extensive cell death of T cell populations under these circumstances, 
especially cells expressing high levels of ARTC2.2 and P2RX7, like CD4+ T 
regulatory cells (Treg) (158). Moreover, even cells that survive isolation steps 
may be compromised for in vitro functional assays (170). 
To tackle this issue, ARTC2.2-specific antagonist nanobodies to block the 
ARTC2.2/P2RX7 signaling axis were developed (166). Previous studies 
successfully used this strategy to recover lymphocytes with high expression of 
ARTC2.2, including Treg and invariant natural killer T (iNKT) cells (170). Two 
recent reports showed that ARTC2.2 blockade also prevents the death of liver 
CD8+ tissue-resident memory T cells (TRM) during tissue preparation (171, 
172). Overall, this indicates that T lymphocytes in nonlymphoid tissues are 
sensitive to death induced by activation of ARTC2.2 and P2RX7. Despite the 
pioneering nature of these reports, several questions remain. First, these 
studies focused on elevated frequency of live cells and short-term functional 
assays, rather than numeric comparisons of cells in the tissues. This made it 
hard to quantify to what extent ARTC2.2 blockade prevented loss of iNKT 
cells.  
Second, iNKT cells are not homogeneous populations, with potential 
differences dictated both by differentiation state and tissue-specific 
microenvironmental signals. iNKT cells are composed of functionally and 
transcriptionally distinct effector subsets that include T-bet+ PLZFlow NKT1, 
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PLZFhigh NKT2, and RORγt+ PLZFintermediate NKT17 cells (12, 24, 136). Notably, 
the previous ARTC2.2 blockade studies focused on liver and spleen iNKT, 
most of which are NKT1 cells. Whether other iNKT subsets co-express 
ARTC2.2 and P2RX7 and whether blockade of this pathway can rescue these 
cells is unexplored. 
In this study, we provide an analysis of co-expression of ARTC2.2 and P2RX7 
in different iNKT subsets, in lymphoid and nonlymphoid tissues. In summary, 
we show that high expression of both molecules correlated with high 
susceptibility to ex vivo cell death during harvest procedures. Moreover, we 
found that blocking ARTC2.2 using nanobodies preserved the cell viability and 
in vitro function, favoring a more precise description of the numeric 
proportions of different subsets, as well as their exact functionality. Finally, we 
explored the possibility of using direct P2RX7 inhibition for the preservation of 
T cell numbers. 
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Results 
ARTC2.2 and P2RX7 are preferentially co-expressed in peripheral NKT1 
cells in lymphoid and nonlymphoid tissues 
We first sought to evaluate the expression of P2RX7 and ARTC2.2 in subsets 
of iNKT cells from an array of lymphoid and nonlymphoid tissues. Previous 
studies indicate that ARTC2.2/P2RX7 activation strongly affects the viability of 
liver iNKT (173). Liver iNKT are predominantly NKT1, and we confirmed that 
liver NKT1 cells express high levels of both ARTC2.2 and P2RX7 (Figure 4-1 
A). Similar expression was seen on NKT1 from other nonlymphoid tissues and 
in the spleen and mLN, whereas mature NKT1 in the thymus showed low 
expression of both ARTC2.2 and P2RX7 (Figure 4-1 B, C). Examination of 
NKT2 and NKT17 cell subsets (12), however, showed distinct expression 
patterns: NKT2 cells expressed high ARTC2.2 and P2RX7 in all sites, 
including the thymus, whereas NKT17 cells expressed low levels of both 
molecules, whether recovered from thymus, LN, or lung (Figure 4-1 B and 
data not shown). 
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Figure 4-1. Expression of ARTC2.2 and P2RX7 in iNKT and CD8+ T cell subsets.  
(A) Representative flow cytometry plot showing expression of ARTC2.2 and P2RX7 or isotype 
control in liver iNKT. (B) Representative plots showing expression of ARTC2.2 and P2RX7 in 
NKT1, NKT2, or NKT17 cell subsets from the indicated tissues. “N/A” means not analyzed 
(because of a paucity of cells of that subset in the tissue). (C) Percentage of NKT1 cells that 
are ARTC2.2+P2RX7+ [as defined by the quadrants in (A)]. (D) Expression of ARTC2.2 and 
P2RX7 in polyclonal CD8+ T cells from the indicated tissues (above) and in virus-specific 
CD8+ T cells 4 wk postinfection (below). For the virus-specific CD8+ T cell analysis, P14 
CD8+ T cells were adoptively transferred into congenic recipient mice (2.5 × 104cells per 
mouse), followed by infection with LCMV Armstrong (2 × 105 PFU, i.p.). After 4 wk, cells were 
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isolated from the indicated tissues. (E) The percentages of ARTC2.2+P2RX7+ cells are shown 
for polyclonal CD8+ T cells in the thymus and spleen, as well as splenic memory P14 cell 
subsets (TCM, TEM, SLO TRM). (F) Percentages of memory P14 cells that were 
ARTC2.2+P2RX7+ in the different organs are shown, as well as polyclonal SI-resident CD8+ T 
cells. (A–F) Data are from three independent experiments, n = 5–6 mice per experimental 
group. 
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ARTC2.2 blockade improves the yield of NKT1 cells in nonlymphoid 
tissues 
Considering the high expression of both ARTC2.2 and P2XR7 in NKT1 cells, 
especially those residing in the nonlymphoid tissues (liver and small intestine), 
we asked whether tissue harvest and processing led to loss of NKT1 cells in 
an ARTC2.2-dependent pathway. To test this, we used a nanobody specific to 
ARTC2.2, previously shown to inhibit this enzyme’s function in Treg cells (173). 
In keeping with previous reports (170, 173), we observed a significantly higher 
yield of NKT1 cells in liver of mice treated with intravenous injection (i.v.) of 
anti-ARTC2.2 30 min prior to sacrifice (Figure 4-2). The action of the ARTC2.2 
blockade was not limited to the liver because we observed a notably higher 
yield (5-fold) of NKT1 cells in the intraepithelial lymphocyte (IEL) of treated 
mice (Figure 4-2). Although not statistically significant, there was also a clear 
trend of higher yield of NKT1 cells in lamina propria (LPL) by pretreatment 
with anti-ARTC2.2 nanobody (Figure 4-2). Importantly, ARTC2.2 blockade led 
to increased numbers of NKT1 cells recovered, which was not specifically 
reported in previous studies (170, 173). In contrast, we did not observe any 
difference in the recovery of NKT1 cells in thymus, spleen, or mLN between 
mice injected with anti-ARTC2.2 nanobody or PBS (Figure 4-2). It is important 
to note that tissue processing of liver and intestines (but not of thymus, 
spleen, or LNs) requires short-term (20–60 min) incubations at room 
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temperature (25°C) or 37°C, conditions that permit ARTC2.2-mediated P2RX7 
pore formation. Together, our data suggest that nonlymphoid tissue 
processing might result in ARTC2.2-mediated loss of NKT1 cells, and 
blockade of this pathway is a crucial step for the recovery of optimal numbers 
of this cell population. 
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Figure 4-2. Blockade of the ARTC2.2/P2RX7 axis improves recovery of NKT1 cells in 
nonlymphoid tissues.  
Number of NKT1 cells recovered in the indicated tissues from mice treated with anti-ARTC2.2 
nanobody or PBS prior to tissue harvest. NKT1 cells are defined as TCRβ+ CD1d tetramer+ T-
bet+. Blue bars represent cells from mice that received PBS, red bars represent cells from 
mice that received anti-ARTC2.2 nanobody. Data are from eight independent experiments 
with two to six mice in each experiment. **p < 0.01. 
 
  
141 
 
Anti-ARTC2.2 nanobody blockade preserves phenotype, functionality, 
and viability of iNKT 
Activation of the ARTC2.2/P2RX7 signaling axis also induces the loss of other 
cell surface molecules (166). Consistent with a previous study (173), we 
observed that in vivo treatment with anti-ARTC2.2 nanobody prevented loss 
of CD27 in both splenic and liver iNKT (Figure 4-3 A). Furthermore, we 
evaluated other surface markers that have been used for phenotyping of iNKT 
and CD8+ T cells. We observed that cell surface levels of CD69 and P2RX7 in 
iNKT were substantially preserved by in vivo treatment of anti-ARTC2.2 
nanobody, whereas expression of ARTC2.2 itself, CD122, and CD4 was not 
affected (Figure 4-3 A). To our knowledge, the nanobody-mediated 
preservation of CD69 and P2RX7 expression in iNKT is a novel finding and 
suggests that some previous studies of iNKT may not faithfully describe their 
phenotype ex vivo. Whether ARTC2.2 activation alters other surface markers 
in iNKT is still unclear and will be a focus of future research. 
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Figure 4-3. Blockade of the ARTC2.2/P2RX7 axis preserves surface molecules, cytokine 
production, and viability of iNKT.  
Blue bars represent cells from mice that received PBS, and red bars represent cells from 
mice that received anti-ARTC2.2 nanobody. (A) Representative flow cytometry plots for 
surface expression of CD27, CD69, P2RX7, ARTC2.2, CD122, and CD4 in spleen and liver 
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NKT1 cells from mice treated with anti-ARTC2.2 nanobody or PBS. (B–D) Liver mononuclear 
cells isolated from mice treated with anti-ARTC2.2 nanobody or PBS were stimulated in vitro 
with presence of PMA/ionomycin for 4 h. (B) Numbers (left column) and frequency of NKT1 
cells among total T cells (TCRβ+) (right column) after in vitro stimulation. (C) Representative 
flow cytometry plots for IFN-γ production in NKT1 cells after in vitro stimulation. (D) 
Frequency (left column) and number (right column) of IFN-γ+ NKT1 cells after in vitro 
stimulation. (E and F) Liver mononuclear cells isolated from mice treated with anti-ARTC2.2 
nanobody or PBS were cultured in vitro for 24 or 72 h. (E) Frequency of live iNKT (viability 
dye negative) after in vitro culture for 24 h (upper row) or 72 h (bottom row). (F) Frequency 
(left column) and number (right column) of live iNKT after in vitro culture for 24 h (upper row) 
or 72 h (bottom row). Data are from four independent experiments, n = 2–10 mice per 
experiment. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Next, we asked whether blockade of the ARTC2.2/P2RX7 signaling axis 
would improve functional properties of iNKT after in vitro stimulation. Liver 
mononuclear cells from mice treated with PBS or anti-ARTC2.2 nanobody 
were cultured in vitro with the presence of PMA/ionomycin for 4 hrs. The 
treatment of anti-ARTC2.2 nanobody prior to tissue harvest not only led to 
much better recovery of iNKT after short-term in vitro stimulation (Figure 4-3 
B) but also to a substantially higher frequency of IFN-γ production by those 
NKT1 cells (Figure 4-3 C, D). 
Recently, there has been an increasing interest in harnessing iNKT for 
immunotherapy, which usually requires prolonged in vitro culture for 
transduction and/or expansion. Therefore, we tested the possibility that 
blockade with anti-ARTC2.2 nanobody might enhance the feasibility of 
culturing iNKT in vitro. Indeed, we observed that in vivo treatment of mice with 
anti-ARTC2.2 nanobody enhanced the number and viability of iNKT after 
short-term in vitro culture by ∼5-fold (Figure 4-3 E, F). Taken together, these 
data show that in vivo treatment of anti-ARTC2.2 nanobody to block the 
ARTC2.2/P2RX7 signaling pathway prior to isolation significantly improves 
viability and functionality of iNKT for in vitro stimulation and cell culture. 
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Discussion 
Early studies indicated that the activation of the ARTC2.2/P2RX7 pathway 
during ex vivo preparation of a single-cell suspension could lead to profound 
apoptosis and dysfunction in Treg and liver iNKT (170). However, the 
expression of ARTC2.2 and P2RX7 in iNKT in tissues other than liver has not 
been extensively evaluated. Moreover, whether ARTC2.2/P2RX7 signaling 
might lead to disproportionate changes in cell number, phenotype, or function 
of specific subsets of iNKT during tissue processing had not been evaluated. 
In the current study, we established a detailed analysis of P2RX7 and 
ARTC2.2 expression in iNKT cells and short-term blockade of this 
ARTC2.2/P2RX7 axis shortly before tissue harvest could significantly improve 
the recovery and ex vivo function of iNKT. Our results suggest that both 
ARTC2.2 and P2RX7 are highly expressed in peripheral but not thymic NKT1 
cells. This might be due to the environmental cues present only in periphery. 
Retinoic acid reportedly induces P2RX7 expression in intestinal lymphocytes 
(174), being a potential factor that influences the expression of ARTC2.2 and 
P2RX7 in iNKT cells residing in nonlymphoid tissues. Whether retinoic acid 
itself or similar molecules drive expression in other tissues is still unknown 
and will certainly be a subject of future studies. Moreover, it is worth 
mentioning that cell-intrinsic factors might also contribute to this phenomenon, 
as NKT2 cells seem to express high levels of ARTC2.2 and P2RX7 regardless 
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in the thymus or periphery, whereas NKT17 cells do not express these 
receptors in either the thymus or periphery. Altogether, these results 
demonstrate considerable heterogeneity in the expression of P2RX7 and 
ARTC2.2 across various subpopulations of T cells (even among iNKT 
subsets), suggesting differential susceptibility to NAD-induced and ATP-
induced cell death and signaling. In the future, it will be important to determine 
whether iNKT differentiation signals override local environmental cues for 
expression of P2RX7 and ARTC2.2 and whether activation of these receptors 
is involved in shaping the representation of distinct iNKT subsets. 
The physiological role of P2RX7 in T cell function and homeostasis is still the 
subject of intense investigation. It has been reported that P2RX7 activation 
can favor mouse CD4+ T cell IL-2 production following re-stimulation and the 
differentiation of Th17 cells but restrains generation of Treg and T follicular 
helper cells (162, 175, 176). Moreover, we recently reported that P2RX7 is 
crucial for establishment of long-lived memory CD8+ T cell populations, 
including TRM (164). Interestingly, our data presented in this article suggest a 
“Jekyll and Hyde” function of this receptor for TRM biology, in which high 
expression of P2RX7 can be beneficial in most cases (e.g., for memory 
establishment) but potentially detrimental if these cells encounter situations 
(such as highly inflammatory environments) in which ARTC2.2 activation by 
NAD may be anticipated. Indeed, a recent report showed P2RX7 to be 
147 
 
detrimental for liver and SI IEL TRM in the presence of sterile inflammation 
(177). It will be important to expand these studies and determine how long-
term survival of various tissue-resident T cell populations, as well as their in 
vivo function, is affected by inflammatory challenge in a P2RX7/ARTC2.2-
dependent way. Likewise, ARTC2.2 and P2RX7 are highly expressed by 
some subsets of iNKT, yet the impact of this expression on differentiation and 
function of these populations is unclear. Furthermore, it will be interesting to 
explore the role of P2RX7 and ARTC2.2 in mucosal-associated invariant T 
cells (71, 120, 132, 136, 178, 179), another innate-like T cell population, in 
future studies. 
Taken together, our results help cement the notion that high expression of 
ARTC2.2 and P2RX7 act as biomarkers for susceptibility to cell death during 
tissue isolation in murine models. This was confirmed by our comprehensive 
ARTC2.2 blockade study. Beyond the scope of previous reports, we showed 
in this study that inhibition of ARTC2.2-mediated cell death not only preserves 
viability of nonlymphoid tissue T cell populations but allows a more accurate 
representation of different subsets among those recovered lymphocytes. 
Moreover, we show this blockade permits the accurate assessment of 
functionality of tissue-resident T cells in vitro, which opens several future 
possibilities—for example, metabolism assays and transduction of T cell 
populations isolated from nonlymphoid sites, both of which have been 
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technically challenging. In summary, we report that short-term blockade of 
ARTC2.2/P2RX7 activation during cell isolation is a crucial technical step for 
the optimal study of the biological characteristics of iNKT in nonlymphoid 
tissues and should be used when practical. 
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Materials and Methods 
Mice 
Six- to ten-week-old C57BL/6 (B6) and B6.SJL (expressing the CD45.1 allele) 
mice were purchased from Charles River Laboratories (via the National 
Cancer Institute). Animals were maintained under specific pathogen-free 
conditions at the University of Minnesota. All experimental procedures were 
approved by the institutional animal care and use committee at the University 
of Minnesota. 
 
Anti-ARTC2.2 nanobody treatments 
To prevent ADP-ribosylation of P2RX7 during harvest procedures, 
experimental mice were injected i.v. with 50 μg of the ARTC2.2 blocking 
nanobody (S+16a; Treg Protector, BioLegend) diluted in 200 μl of PBS, 30 
min prior to sacrifice (171). Control mice received 200 μl of vehicle (PBS) at 
the same time. 
 
Flow cytometry 
Lymphocytes were isolated from tissues, including spleen, skin-draining lymph 
nodes (LN), mesenteric LN (mLN), thymus, blood, lung, small intestine (SI) 
intestinal epithelium, SI lamina propria (LPL), and liver, as previously 
described (127, 180) with the indicated mouse pretreatments (vehicle, 
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ARTC.2.2 nanobody). Briefly, this involved digestion at 37°C for 30 min in 
DTE (SI intestinal epithelial lymphocyte [IEL]) or 30–45 min in Type I 
Collagenase (SI LPL, lung), with stirring, followed by Percoll gradient 
centrifugation at room temperature. For secondary lymphoid organs (SLO), 
processing was followed by RBC lysis with ACK lysis buffer, at room 
temperature. Direct ex vivo staining and intracellular cytokine staining were 
performed as described previously (93, 127). Foxp3 Fix/Perm kit 
(eBioscience) was used for intracellular detection. Fluorochrome-conjugated 
Abs were purchased from BD Biosciences, BioLegend, eBioscience, Cell 
Signaling Technology, Tonbo, or Thermo Fisher Scientific. iNKT were detected 
using CD1d tetramers loaded with PBS-57 (provided by the National Institutes 
of Health Tetramer Facility) and TCRβ staining, and the distinct iNKT subsets 
were distinguished as described previously (12, 24); briefly, the NKT1 cells 
were defined as PLZFlow T-bet+, NKT2 cells were defined as PLZFhigh ROR-
γt− T-bet−, and NKT17 cells were defined as PLZFintermediate ROR-γt+. For 
survival assessment, cells were stained with Live/Dead dye (Tonbo 
Biosciences). Flow cytometric analysis was performed on an LSR II or LSR 
Fortessa (BD Biosciences), and data were analyzed using FlowJo software 
(Tree Star). 
 
In vitro culture experiments 
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To measure the proliferation, survival, and cytokine production of liver iNKT 
and spleen/SI memory (P14) CD8+ T cells, cells from experimental mice were 
isolated as described above and stimulated in vitro with vehicle (RPMI 1640), 
PMA (20 ng/ml) plus ionomycin (1 μM). Cells were cultured for 4, 24 and 72 
hrs. For all experiments, complete RPMI media (RPMI 1640 supplemented 
with 10% FBS, 100 U/ml penicillin/streptomycin, 2 mM l-glutamine) was used. 
 
Statistical analysis 
Statistical differences were calculated by using unpaired two-tailed 
Student t test or one-way ANOVA with Tukey posttest, where indicated. All 
experiments were analyzed using Prism 5 (GraphPad Software). The p values 
<0.05 (*), <0.01 (**), <0.001 (***), or <0.0001 (****) indicated significant 
differences between groups, and nonsignificant differences were indicated 
with “ns”. 
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